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MODELING CONGENITAL DISORDERS OF GLYCOSYLATION IN C. 
ELEGANS: GENETIC INFLUENCES AND STRUCTURAL CONSEQUENCES 
OF A/-LINKED GLYCOSYLATION 
by 
Weston Booth Struwe 
University of New Hampshire, May 2009 
The attachment of oligosaccharides to the amide nitrogen of asparagine 
side chains in proteins is a fundamental process occurring in all metazoans. This 
process, known as A/-glycosylation, is complex and is achieved by the precise 
interactions of various cellular components. The initial stage of A/-glycosylation 
occurs in the endolasmic reticulum and is preserved among eukaryotes. Glycans 
are further developed in the Golgi and the structural complexity depends greatly 
on the animal species, tissue and developmental stage. Oligosaccharides are 
unique biomolecules because unlike DNA or proteins, no primary sequence 
exists nor is its' synthesis template driven. A major goal of glycobiologist is to 
understand how glycan structures arise and their impact in biological systems. 
Defective enzymes or components in this pathway cause congenital 
disorders of glycosylation (CDG) in humans. This disease is very rare, but 
exceedingly life-threatening. The CDGs are inherited in an autosomal recessive 
manner and clinical manifestations range from severe to mild. Most commonly, 
the disorders begin in infancy; manifestations range from severe developmental 
xii 
delay and hypotonia with multiple organ system involvement to hypoglycemia 
and protein-losing enteropathy with normal development. Infants and children 
with CDG require nutrition supplements for maximal caloric intake and/or 
nasogastric tube or gastrostomy tube feedings. Orthopedic issues in adults 
require physical therapy, wheel chairs, transfer devices, and surgical treatment of 
scoliosis as needed. 
The goals of researchers today are to identify further types of CDG, 
identify the defects in each type, and find means for management of the disease. 
Paramount to CDG treatment and care is an understanding of the mechanisms of 
/V-glycosylation and factors that influence the pathology of the disease. 
Ultimately CDG treatment will stimulate correct glycosylation at the cellular level 
and potentially compensate for defects and restore normal glycosylation levels. 
Xll l 
CHAPTER 1 
PERSPECTIVES OF GLYCOBIOLOGY 
The concept of the central dogma of molecular biology is no longer 
adequate to explain or understand the spectacular complexity of biological 
systems. Today, the field of systems biology adds to the notion of the central 
dogma which states that three major classes of biopolymers exist to describe the 
normal flow of biological information. In addition to the paradigm of DNA-RNA-
protein, systems biology researchers focus on the systematic study of complex 
interactions in biological systems that include DNA, RNA, proteins, lipids, 
carbohydrates, non-coding RNAs and small molecule metabolites. 
The discipline of glycomics is one within the large field of systems biology 
that aims to understand glycan structures and functions. Functional glycomics 
aims to tackle three general questions: 1) how glycans function in cellular 
communication; 2) what is the basis for specificity between proteins and glycans; 
3) how glycan diversity and microheterogeneity results as a function of biology in 
development and disease. 
In contrast to DNA, RNA and proteins, carbohydrates form branching 
structures and as a result, a relatively small set of monosaccharides (Table 1) 
can form considerably complex structures. Furthermore, glycans are not 
template generated biomolecules such as DNA, RNA and proteins. Sythesis 
relies on the transcription and translation of glycosylation enzymes that are 
1 
localized throughout the cell. The dynamics and complexity of glycan synthesis, 
coupled with the well established extrinsic factors makes glycobiology one of the 
most challenging disciplines in research today. 
Carbohydrates, when attached to proteins or lipids, form large complex 
biomolecules termed glycoconjugates. The glycan portion of glycoconjugates fall 
into three catagories: those 
attached to lipids, and those 
attached to proteins either 
through a nitrogen atom {N-
linked) or through an oxygen 
atom (O-linked). The 
attachment of glycans 
influences protein structure 
and function, as well as the 
localization of cell surface 
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Table 1. Common monosaccharides by type 
Glycans can confer cell-type specificity and are critical components of cell-to-cell 
signaling (Varki 1993). Carbohydrates are also involved in the immune response 
and host-pathogen interactions (Griffitts, Haslam et al. 2005). Moreover, 
changes in A/-glycan biosynthesis have been identified as key components in 
tumor progression in mice and humans (Fuster and Esko 2005). 
Carbohydrate protein posttranslational modifications are a functionally 
important process that is vital in multiple biological systems. A/-linked glycans 
2 
are highly diverse branched structures that are attached to asparagines residues 
of polypeptide chains within the Asn-X-Ser/Thr sequon (Marshall 1974; Hubbard 
and Ivatt 1981). /V-glycosylation is universal of eukaryotes and between 25% 
and 50% of proteins encoded by eukaryotic genomes are estimated to be N-
glycosylated (Apweiler, Hermjakob et al. 1999; Dennis, Granovsky et al. 1999; 
Hirabayashi, Hayama et al. 2002). The mammalian glycome is estimated to 
range between hundreds and thousands of glycan structures suggesting it could 
be larger than the proteome (Ohtsubo and Marth 2006). Despite great advances 
in glycobiology, there remains much to be known about the roles of 
glycoconjugates, their metabolism and influence in diseases. 
1.1 AMinked Glycan Biosynthesis: Endoplasmic Reticulum 
The structural diversity of A/-glycans is determined through a complex 
biosynthetic pathway that begins on the surface of the endoplasmic reticulum 
(ER). The early stages of A/-glycan biosynthesis is conserved among S. 
cerevisiae, C. elegans and vertebrates (Huffaker and Robbins 1982; Altmann, 
Fabini et al. 2001). The biochemical pathway for A/-linked glycan synthesis 
occurs in four distinct stages: (1) formation of a lipid-linked precursor 
oligosaccharide; (2) en bloc transfer of the oligosaccharide to a nascent 
polypeptide; (3) trimming of oligosaccharides in the endoplasmic reticulum and 
Golgi; (4) addition of new sugars in the medial and frans-Golgi. All eukaryotes 
share the first three steps of A/-glycosylation, but greater glycan complexity seen 
3 
in higher species is due to extensive processing that occurs in the Golgi. The 
formation of the dolichol-linked oligosaccharide precursor, GIC3Man9GlcNAc2 
which is constructed on both sides of the ER, is the building block on which N-
glycans become more elaborate (Figure 1). 
0 Glucose (Glc) 
® Mannose (Man) 
| /V-acetylglucosamine (GlcNAc) 
P-Dol • • • 
U D P — | J UDP— • 
P-P-Dol 
P-P-Dol „_ P-P-Dol P-P-Dol 
• Fhppase • 
Cytosolic side of endoplasmic reticulum Lumen of endoplasmic reticulum 
Figure 1. Synthesis of the lipid-linked oligosaccharide precursor in the 
endoplasmic reticulum. 
The assembly of the 14 residue LLO molecule relies on the step-by-step 
action of substrate specific enzymes that build the precursor structure. The 
transfer of the 14 residue precursor oligosaccharide begins during the assembly 
of the polypeptide in the lumen of the ER and is facilitated by the 
oligosaccharyltransferase complex. The yeast and vertebrate 
oligosaccharyltransferase complex are significantly complex and consist of seven 
and eight subunits respectively (Kelleher and Gilmore 2006). Once the LLO is 
T * T * T * ? 
± GDP-® ± Dol-P-® X Dol-P-0 ± 
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transferred to the polypeptide in the lumen of the ER, the glycopeptide 
undergoes immediate quality control processing before moving to the Golgi. 
As the nascent glycoprotein begins transport from the ER, glucosidase I 
removes the outer most glucose residue. Glucosidase II then removes the 
second proximal glucose leaving a glycoprotein with a single terminal gjucose. 
Subsequently, two quality control lectins, calnexin and calreticulin ensure proper 
folding by binding to the monoglucosylated glycopeptide (Figure 2). Calnexin 
and calreticulin interact with ERp57, a thiol-disulfide oxidoreductase, which 
assists in the folding of luminal ER glycoproteins. Glucosidase II acts again by 
cleaving the third glucose and the calnexin/calreticulin complex dissociates from 
the glycoprotein. 
At this point the glycoprotein can follow two distinct routes depending on 
proper protein folding. If the calnexin/calreticulin complex determines the 
glycoprotein to be properly folded, it will continue towards the Golgi in the 
intermediate compartment (IC) for further processing alone or with the aid of an 
additional ER lectin, ERGIC-53. If the glycoprotein is partially unfolded, it is 
retained in the ER and reglucosylated by a luminal glucosyltransferase and will 
once again interact with calnexin/calreticulin and ERp57 to achieve proper 
folding. If the protein is folded correctly, the ER a1,2-mannosidase I cleaves a 
specific terminal mannose residue from the Man9GlcNAc2 oligosaccharide to 
generate Man8GlcNAc2 before the glycoprotein exits the ER. However, if correct 
folding is not achieved, the glycoprotein will trigger the endoplasmic reticulum-
5 
associated protein degradation (ERAD) pathway and will be translocated to the 
cytoplasm and digested in the proteasome (Jones, Krag et al. 2005). 
If unfolded proteins accumulate in the endoplasmic reticulum, the cell can 
initiate the unfolded protein response (UPR). Transit from the ER to the Golgi 
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Figure 2. The calnexin/calreticulin cycle. 
Adapted from Jones et. al. 2005 
influx of nascent, unfolded polypeptides exceeds the folding and/or processing 
capacity of the ER, the normal physiological state of the ER is perturbed. A high 
concentration of partially folded and unfolded proteins predisposes protein-
folding intermediates to aggregate. The UPR provides a mechanism by which 
6 
cells can rapidly adapt to alterations in protein-folding loads in the ER lumen by 
expanding the capacity for protein folding. A variety of factors that disrupt protein 
folding in the ER lumen also activate the UPR. These include changes in 
intralumenal calcium, altered glycosylation, nutrient deprivation, pathogen 
infection, expression of folding-defective proteins, and changes in redox status 
(Malhotra and Kaufman 2007). Additionally, perturbations of ER function can be 
caused by overexpressing large and heavily modified proteins or small 
structurally simple proteins (Schroder and Kaufman 2005). 
In response to ER stress, the ER-localized transmembrane signal 
transducers are activated to initiate adaptive responses. These transducers are 
activating transcription factor 6 (ATF6), inositol requiring kinase 1 (IRE1), and 
double-stranded RNA-activated protein kinase (PKR)-like endoplasmic reticulum 
kinase (PERK). The most immediate response to ER stress is the reversible 
attenuation of mRNA translation, thereby slowing the influx of newly synthesized 
polypeptides. This response is signaled through PERK by phosphorylation of the 
eukaryotic translation initiation factor 2 on the alpha subunit (elF2a) which 
inhibits the formation of the active elF2 complex. elF2 is required for the ternary 
complex elF2-GTP-tRNA that recognizes AUG codons and is responsible for 60S 
ribosomal subunit assembly. The second response to ER stress is up-regulation 
of UPR genes that increase the folding capacity within the ER. IRE1 is a protein 
kinase that when activated undergoes frans-autophosphorylation to activate its' 
RNase activity. Active IRE1 removes a 26 nucleotide intron from XBP1 mRNA. 
Spliced XBP1 is a transcriptional activator of a wide variety of UPR target genes 
7 
such as ERAD and chaperones. The third sensor in the UPR, ATF6, acts by 
activating UPR-responsive genes after being localized to the Golgi. The two 
active forms, ATF6a and ATF6(3, translocate to the nucleus from the Golgi where 
it binds to the ATF/cAMP response element (CRE) and the ER stress responsive 
element (ERSE-1) to activate UPR chaperones. If the UPR fails to resolve the 
protein-folding defect and ER stress, apoptosis is activated through 
mitochondrial-dependent and independent pathways. However the relationship 
between ER stress and apoptosis remain to be defined as well as the frequency 
of this event. Seemingly, the unfolded protein response is cell-type specific and 
subject to modulation according to the needs of individual cells. 
1.2 /V-linked Glvcan Biosynthesis: Golgi 
During healthy secretion of nascent proteins, newly synthesized 
glycoproteins exit the ER by forming the intermediate compartment (IC) or 
vesicular-tubular clusters (VTCs) on its way to the Golgi apparatus, the hub of 
the secretory pathway. ER export of immature glycoproteins is mediated by COP 
II coated vesicles and all AMinked glycoproteins at this stage possess the 
Man8GlcNAc2 precursor oligosaccharide. The components involved in COP II 
vesicle formation are essential for cell viability in yeast and are conserved among 
eukaryotes (Duden 2003). The assembly of the COP II coat on the ER 
membrane is initiated by guanine nucleotide exchange of the GTPase Sarlp 
(Futai, Hamamoto et al. 2004). The presence of Sar1p-GTP leads to the 
8 
recruitment of additional coat components, namely two hetero-dimeric protein 
complexes; Sec23/24p and Sec13/31p (Matsuoka, Orci et al. 1998). Once the 
GTP-rich Sari p is embedded in the bilayer of the ER membrane and Sec23/24p 
and Sec13/31p are recruited, budding and vesicle formation occurs. 
COP II vesicular budding has been observed in both mammalian and 
yeast cells by time lapse 
fluorescence microscopy, 
using chimeras of a COP II 
subunit with green fluorescent 
protein (Duden 2003). After 
COP II buds are released 
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Figure 3. Common AM inked glycan types. 
uncoat, allowing them to fuse with other COP II vesicles which forms the 
intermediate compartment (IC). The IC moves towards the Golgi along 
microtubule tracks and docks to the c/s-Golgi where it unloads its cargo. 
Subsequently, COP II coat proteins are recruited back to the ER to repeat the 
cycle. In addition to COP II coat proteins, COP I is a second class of 
evolutionary conserved coat proteins that is also crucial for directing the transfer 
of material within the Golgi. 
In COP II vesicles deliver Man8GlcNAc2 containing glycoproteins in the 
c/s-Golgi where three additional a-mannosidases (IA, IB and IC) reduce the 
oligosaccharide to Man5GlcNAc2. This structure serves as the substrate for 
complex, hybrid and high mannose /V-glycans (Figure 3) formed in the medial 
9 
and trans-Go\g\ by means of assorted glycosyltransferases. Next the 
glycoprotein may move forward to a high-mannose type or by the action of N-
acetylglucosaminyltransferase-l (GnT-l), it may proceed to the complex and 
hybrid assembly pathway (Figure 4). GnT-l adds a A/-acetylglucosamine residue 
in a (31-2 linkage to the terminal end of the a1,3-linked mannose residue. After 
the action of GnT-l the glycan may enter hybrid glycan synthesis where the 
remaining mannose residues remain and extensions build upon the 
GlcNAci Man5GlcNAc2 oligosaccharide. 
For complex structure synthesis, a-mannosidase II removes the two 
terminal mannose residues on the crt ,6 arm and distinct GlcNAc-transferases 
extend the structure of the glycan. These GnT enzymes, II through V, are found 
in the medial Golgi and define different branching patterns common of complex 
/V-glycans. GnT II adds a GlcNAc to the a1,3 arm of the Man3GlcNAc2 core. 
GnT III adds a bisecting (31 -4 linked GlcNAc to the core mannose residue. 
Likewise, GnT IV and GnT V add GlcNAc residues to the 1,3 arm and 1,6 arm to 
generate tri-antennary and tetra-antennary forms, respectively (Taylor and 
Drickamer 2003). Complex branched structures are typically extended by the 
addition of a single galactose and sialic residue to each GlcNAc residue. The 
enzymes responsible for these additions are found further along in the secretory 
pathway in the trans Golgi and the frans-Golgi network (TNG). Additionally, 
fucosyltransferases and other GnT enzymes add to the complexity of hybrid and 
complex glycan structures at different locations on the glycan core and terminal 
residues. After generating glycan structures in the medial and trans Golgi, the 
10 
maturing glycopeptide enters the frans-Golgi network and is localized to the cell 
surface or within the cell. 
Despite an understanding of the principal biosynthesis of /V-linked 
glycosylation, the extent of diversity and number of glycan structures present on 
proteins is still unclear. In spite of the structural information that has been 
gathered to date, the mechanisms in secretory pathway that contribute to the 
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Figure 4. Processing of the precursor LLO. The LLO is trimmed and modified to 
generate high-mannose, hybrid or complex type oligosaccharides in the Golgi. Three 
mannose residues are trimmed from the GlcNAc5Man8 containing polypeptide in the cis-
Golgi. This structure is the scaffold for high-mannose biosynthesis. Alternatively, 
GlcNAc transferase I (GnT-l) can add a A/-acetylglucosamine residue on the 3-arm of the 
oligosaccharide. This structure is a precursor for complex and hybrid biosynthesis and 
after the trimming of two additional mannose residues by Golgi mannosidase II, the 
glycan can undergo complex type biosynthesis. During hybrid and complex assembly 
various glycosyltransferases, such as galactosyltransferases, sialyltransferases and 
fucosyltransferases, can modify the structure at different locations. 
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1.3 Biosynthetic Complexity of A/-Iinked Glycans 
In addition to the inherent complexity of glycoconjugates, a particular 
oligosaccharide of a glycoprotein may occur in forms that differ in one or more of 
its oligosaccharide residues, a trend known as microheterogeneity. Many factors 
influence a protiens' glycomer distribution such as transport rates from the ER to 
the Golgi, the duration glycoconjugates are in the Golgi, sugar nucleotide 
metabolism, and localization of glycosyltransferases in the Golgi (Hossler, 
Mulukutla et al. 2007). By and large the diversity of glycan structures is due to 
over 200 different glycosyltransferases located in the Golgi (Opat, van Vliet et al. 
2001). On the other hand, the precise localization of only a small number of 
these glycosyltransferase enzymes within the Golgi has been determined 
through sub-cellular fractionation and immuno-labelling of thin sections followed 
by electron microscopy (Eisner, Hashimoto et al. 2003). 
The gene expression of glycosyltransferases, glycosidases and high-
energy sugar transporters alter the glycan assembly machinery in the Golgi and 
ultimately affect the structure of A/-linked glycans. Golgi resident glycosylation 
enzymes are present in a nonuniform steady-state distribution throughout each 
cisternae (Ungar, Oka et al. 2002). To generate this non-uniform distribution, the 
enzymes and associated substrates transporters must be first transported to a 
specific Golgi cisternae, after which their localization must be maintained through 
a combination of retention, retrieval or replacement (Ungar, Oka et al. 2006). 
Glycosylation enzymes are transported to one of three discrete cisternae, or 
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stacks, in the Golgi and are retained in that location unless they inadvertently 
move. For example, A/-acetylglucosaminyltransferase I and Mannosidase II are 
localized in the c/s/medial Golgi, while galactosyltransferase and sialyltransferase 
are mostly found in the frans-Golgi (Nilsson, Pypaert et al. 1993; Rabouille, Hui 
et al. 1995). If an enzymes' location becomes disoriented then it is retrieved by 
vesicular transport mechanisms and returned to the appropriate site by means of 
intra-Golgi COP I vesicles (Harris and Waters 1996; Martinez-Menarguez, 
Prekeris et al. 2001). 
What determines A/-glycan microhicroheterogeneity is the transcription, 
translation and localization of these glycosylation enzymes as well as structural 
dynamics of the Golgi, which has yet to be fully defined. The structural diversity 
and complexity of giycans is a distinguishing characteristic of the Golgi and its 
non-template-based glycan biosynthesis. Even more intriguing is the manner in 
which the Golgi functions. Two theories exist concerning the nature of transport 
of glycoproteins across the Golgi stack. One called vesicular transport is carried 
out by budding and fusing among static cisternae by means of anterograde 
transport vesicles. The second, called cisternal maturation, suggests that the 
Golgi cisternae themselves are constantly being formed at the cis face of the 
Golgi by the fusion of ER-derived vesicles, particularly COP II vesicles (Figure 5) 
(Pelham and Rothman 2000). Currently no data exists on which model is 
correct, although the cisternal maturation model is gaining favor. Additionally, 
some propose that neither model is mutually exclusive and that the true nature of 
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Figure 5. Anterograde vesicular transport and cisternal maturation: two models 
of Golgi morphology, (a) In anterograde transport cargo from the ER (green) 
approaches and fuses with the c/s-Golgi. This cargo with subsequently bud and fuse 
(yellow) with each cisternae until it exits the frans-Golgi as mature glycoconjugates 
(brown). Retrograde vesicles (blue) return from downstream cisternae and return Golgi 
enzymes to their proper site, (b) In cisternal maturation, the Golgi cisternae are 
constantly being formed at the cis face of the Golgi from cargo vesicles from the ER 
(green). At the trans surface, cisternae are forming into vesicles (brown) intended for 
secretion or trafficking. Similarily to anterograde transport, cisternal maturation 
mechanisms require retrograde transport of Golgi proteins (blue) but at a much greater 
rate. 
The fundamental difference between the two models is the differential 
movement of resident and cargo proteins. It is interesting to note that newly 
synthesized glycoproteins are segregated away from the resident proteins 
throughout the pathway in both models. What is known of the Golgi is that each 
cisternae functions specifically and is a fully functional unit, but not why or how 
these stacks aggregate and connect to form the complete functional Golgi 
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complex. During anterograde vesicular transport, cargo molecules 
(glycoproteins) move forward through the Golgi while resident proteins 
(glycosyltransferases) are specifically retained. 
Alternatively, the cisternal maturation model proposes that the cargo 
molecules move passively as the cisternae mature towards the frans-Golgi and 
resident proteins are recycled by retrograde transport to establish the non-
uniform concentration across the Golgi. Inherent to both models is the 
dependency of localization, or retrograde transport, of resident proteins by COP I 
vesicles. COP I coat proteins mediate Golgi to ER and intra-Golgi traffic and 
help maintain the normal structure of the Golgi complex through retrograde 
localization of machinery proteins (Harris and Waters 1996; Love, Lin et al. 1998; 
Lanoix, Ouwendijk et al. 2001). In vesicular transport retrograde transport is only 
required if resident proteins unintentionally move from their precise cisternae. 
However, in the maturation model where resident enzymes travel with the cargo 
towards the trans-Golgi network, retrograde transport is required at a greater 
rate. 
Before live cell imaging and the advent of green fluorescent protein (GFP) 
tags, both the ER and Golgi were thought as relatively stable structures, an 
assumption that led to the vesicular transport model. This was shown by 
Jamieson and Palade, that in the absence of protein synthesis, the secretory 
pathway remained intact (Jamieson and Palade 1968). The number of Golgi 
cisternae remained constant and the Golgi as a whole appeared 
indistinguishable to conditions when protein synthesis occurred. In spite of this, 
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the fact that vesicular transport could not explain how macromolecular 
complexes, which are too large to fit in an intra-Golgi vesicle, could progress 
between the Golgi cisternae was ignored (Brown 1969; Marchi and Leblond 
1984). Additionally, during the construction of complex glycans, it was assumed 
that glycosyltransferases were not allowed to mix with one another. This belief 
further reinforced the idea that strict compartmentalization was required which 
fitted with the vesicular transport model (Eisner, Hashimoto et al. 2003). In 
reality resident glycosyltransferases exist in mixtures in the Golgi stacks and 
compete for substrates (Nilsson, Pypaert et al. 1993). 
The case for vesicular transport became increasingly vulnerable when 
large biomolecules (i.e. collagen) are considered to traverse the secretory 
pathway. Given their sheer size, it is difficult that such molecules could move 
forward in the pathway based on the 50 nm diameter of COP I and COP II 
vesicles. Studies have shown that collagen matures into fibrinous material in the 
lumen of the Golgi (Marchi and Leblond 1984) which suggest an additional 
scenario where larger cargo could be excreted through the Golgi as a collection 
of cisternae that mature with the constant input of new material. What was not 
know at this time was that the Golgi is subject to extensive recycling of resident 
components and have long half-lives (Eisner, Hashimoto et al. 2003). A typical 
glycosyltransferase has a half-life of -20 hours, in dividing cell tissue culture, 
which typically divide every 20 hours. Additionally, the rate of glycosylation 
enzyme(s) synthesis is low, which causes the cell to recycle them efficiently and 
effectively. In addition to these studies, it was shown through brefeldin A 
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disruption that the Golgi could completely be absorbed into the ER. When BFA 
was removed, the Golgi would reassemble within a short period of time (Misumi, 
Misumi et al. 1986; Lippincott-Schwartz, Yuan et al. 1989). 
The plasticity of the Golgi, the limiting size of its transport vesicles and the 
observation that glycosylation enzymes are not strictly compartmentalized has 
mired the legitimacy of the vesicular transport model. Despite this evidence, the 
maturation model is not without faults. A maturation model situation would infer 
that cargo entering the Golgi would move through and exit the pathway at the 
same rate. This is not the case, as seen with mucin and other highly 
glycosylated proteins, that are know to spend longer periods in the Golgi. Some 
answer that COP vesicles mediate retrograde transport to counter the cisternal 
maturation when needed (Eisner, Hashimoto et al. 2003). The extent of 
evidence that supports both models of intracellular transport highlights the lack of 
knowledge about the secretory pathway and even more so the dynamics of 
glycosylation in which this organelle is paramount. 
The connection between Golgi morphology and glycosylation is significant 
and understanding cellular activity of these principles is perhaps the next step in 
glycan metabolism. The ability of the Golgi to mediate alterations in glycan 
structure is based on many factors and although the assembly pathway is 
somewhat known, glycan function remains obscure. 
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1.4 JV-glycan Structure-Function Relationship 
Deciphering the association between a particular glycan structure and its 
function is an essential question that challanges glycobiologists. Presently, more 
than 7000 glycan structures have been determined, but their significance in 
cellular function remains to be established (Srivastava 2008). Some suggest that 
glycomics is at least an order of magnitude more difficult than proteomics (Dove 
2001). Considering the complex diversity of glycans and how they influence 
proteins, it is no surprise that Schachter questions, "will it ever be possible to 
determine the role that a specific post-translational modification plays in the 
function of a specific protein for every protein in the genome" (Schachter, Chen 
et al. 2002). Nonetheless, notable advances have been made in elucidating the 
role of /V-linked glycans. It is known that glycans influence cell growth and 
development, tumor growth and metastasis, anticoagulation, immune recognition 
and response, cell-cell communication and microbial pathogenesis (Raman, 
Raguram et al. 2005). 
The goal of functional glycomics is to assign a specific glycan(s) to a 
particular protein and determine its function. There is increasing interest in 
functional glycomics and several international collaborative effects have been 
established, striving to explain the biological roles of glycans. This collaboration, 
which includes the Consortium for Functional Glycomics, EuroCarb and the 
Japanese Consortium for Glycomics, has collected a list of 200 human genes 
corresponding to glycosyltransferases. Much of this data has been used to 
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generate cell culture and whole-organism knockouts to understand how genotype 
influences phenotype. In addition to the functional genetics methodology of 
glycomics, considerable advances have been made in the development of 
bioinformatics platforms, lectin databases, glyco-gene microarrays, structure 
databases and tools to investigate the conformational aspects of glycans and 
their corresponding protein component. The complexity in the field of glycomics 
requires a systems approach that investigates biosynthesis, structural analysis 
as well as glycan-protein interactions to delineate glycan-structure relationships. 
The many experimental approaches taken to understand the roles of 
glycans include inhibition of glycosylation, alterations to processing mechanisms, 
elimination of glycosylation sites, enzymatic or chemical de-glycosylation of 
complete glycan chains and the study of glycosylation mutants (Varki 1999). The 
consequences of altering glycosylation are highly unpredictable and the effects 
can range from virtually undetectable to lethal. Moreover the same studies or 
changes in specific aspects of glycosylation can change depending on the animal 
model used. In many cases, investigating the role or structure of glycans through 
knockout models is beneficial, but the universal presence of glycoconjugates 
makes understanding cellular phenotypes as a function of its gene and protein 
components difficult. 
On the most basic level, glycans alter proteins on an intrinsic (structural) 
level or extrinsically where the carbohydrate modulates the function of the 
underlying peptide. The external location of glycans on proteins can serve as a 
shield, protecting the protein from proteases or antibodies. Carbohydrates are 
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exceedingly hydrophilic which alters the conformation and solubility of proteins. 
Protein folding is driven by its folding energy landscape initiated by hydrophobic 
collapse. The free energy of each possible conformation is largely determined by 
the primary sequence and by the contacts of its nonpolar groups. The addition of 
carbohydrates during translation in the ER greatly alters the energy landscape of 
proteins. Depending on the size, glycoform and extent of occupancy, a protein 
will fold until a native structure is formed and the lowest free energy is reached. 
Individual protein motifs (a-helices and (3-turns) fold within microseconds, which 
is why quality control measures are in place to determine proper folding before 
any protein exits the ER (Schroder and Kaufman 2005). 
The presence or absence of glycans can affect the primary function or 
activity of a protein. For example, (3-human chorionic gonadotrophin (P-HCG) 
can bind with similar affinity to its receptor with and without its glycan component. 
However, in its deglycosylated form (3-HCG fails to stimulate adenylate cyclase 
(Varki 1999). Glycans can also influence the longevity of proteins to which they 
are attached. In the case of human erythropoietin, the presence of sialic acid on 
its terminal branched increase the half-life, but decreases the activity in vitro. 
The extent of branching can determine binding of erythropoietin to its receptor in 
specific tissues (Takeuchi and Kobata 1991). The tuning effect of glycan 
sequences act in protein function, although the effect may be a change in the 
binding mechanism seen through changes in glycan/protein structure. 
Similarily, glycans act as specific ligands for endogenous and exogenous 
receptors. The role of glycans and ligands for lectins is perhaps the most 
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common functional aspect of carbohydrates in cellular systems. For example, 
the glycoprotein hemagglutinin (HA) on the surface of the avian influenza virus is 
responsible for binding to the cell being infected. Avian HA binds specifically to 
a2-3 sialylated glycans, which are absent in the respiratory tract of humans. It is 
thought that a switch in HA binding from a2-3 sialylated glycans to a2-6 sialylated 
glycans, which are present in humans, enables infections in humans 
(Chandrasekaran, Srinivasan et al. 2008). The future directions will aim to define 
not only the nature of binding interactions of carbohydrates to lectins, but the 
elucidation of the nature of the biological functions of these molecules. 
Currently functional glycomics lacks any high-throughput strategies for 
analyzing the structure and function of each carbohydrate moiety. Structural 
characterization of the vast heterogeneity of glycans generated from their non-
template and poorly understood synthesis is only one important aspect of 
functional glycomics. The challenges of glycomics include understanding glycan 
structure as a function of extracellular signaling, determining the basis for glycan-
protein specificity and interactions, and elucidating how glycan diversity is 
generated as a function of its biosynthesis. Furthermore the biology and 
biosynthesis of glycosylation on a cellular level remains unclear. Addressing the 




CONGENITAL DISORDERS OF GLYCOSYLATION 
Protein A/-glycosylation is an essential and pervasive event in eukaryotic 
development. Mild defects in this process lead to deficiencies in cellular growth 
and function and are associated with disease. Most notable are a group of 
inherited autosomal recessive human disorders called congenital disorders of 
glycosylation (CDG). CDGs are categorized as type I or type II depending on the 
location in the biochemical pathway where the defect occurs. Type I disorders 
are characterized as defects of enzymes in the lipid-linked oligosaccharide 
assembly pathway. Currently there are 12 known defects, or subtypes, in this 
category (Table 2). Type II disorders are deficiencies of enzymes involved in the 
trimming and processing of the protein bound oligosaccharide in the Golgi. To 
date there are eight defective enzymes in type II CDG (Jaeken and Matthijs 
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Developmental delay, hypotonia, 
esotropia, lipodystrophy, 
cerebellar hypoplasia, stroke-
like episodes, seizures 
Hepatic fibrosis, protein losing 
enteropathy, coagulopathy, 
hypoglycemia 
Moderate developmental delay, 
hypotonia, esotropia, epilepsy 
Profound psychomotor delay, 
optic atrophy, acquired 
microcephaly, iris colobomas; 
hypsarrhythmia 
Profound psychomotor delay, 
severe developmental delay, 
optic atrophy, acquired 
microcephaly, epilepsy, 
hypotonia, mild dysmorphism, 
coagulopathy 
Short stature, icthyosis, 
psychomotor retardation, 
pigmentary retinopathy 





enteropathy, renal failure, 
hypoalbuminemia, edema, 
ascites 
Normal at birth; developmental 
delay, hypomyelination, 
intractable seizures, iris 
colobomas, hepatomegaly, 
coagulopathy 
Severe developmental delay, 
hypotonia, seizures, 
microcephaly, exotropia 
Severe psychomotor retardation, 
hypotonia, acquired 
microcephaly, intractable 
seizures, fever, coagulopathy, 
nephrotic syndrome, early death 


























Conserved oligomeric Golgi 
complex subunit 7 
CMP-Sialic acid transporter 
Conserved oligomeric Golgi 
complex subunit 1 
Conserved oligomeric Golgi 
complex subunit 8 
Recurrent infections, persistent 
neutrophilia, developmental 









jaundice, recurrent infections, 
cardiac failure 
Thrombocytopenia, no 
neurologic symptoms, normal Tf, 
abnormal platelet glycoproteins 
Failure to thrive, hypotonia, 
growth retardation, cardiac 
failure, microcephaly, mild 
hepatosplenomegaly, mild 
psychomotor retardation, 
cerebellar and cerebral atrophy 
Facial dysmorphism, 
encephalopathy, hypotonia, 
status epilepticus (recurrant 
seizures), ataxia, progressive 
microcephaly, esotropia and 
eyelid pseudoptis, cerebellar 
atrophy 
Table 2. Congenital disorders of glycosylation by type and subtype. 
The importance of protein glycosylation is dramatically illustrated by the 
severity of the disease, although the history of the CDG is comparatively concise. 
Congenital disorders of glycosylation (formally known as carbohydrate-deficient 
glycoprotein syndromes) was initially discovered in 1980 by the observation of 
serum protein abnormalities in monozygous twin sisters with psychomotor 
retardation, decreased thyroxine-binding globulin levels and increased 
arylsulphatase A activities (ASA) (Jaeken, Vanderschuerenlodeweyckx et'al. 
1980). 
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However it was not until 1983 when the nature of the problem was 
identified by a shift in the isoelectric focusing (IEF) profile of serum transferrin. 
This newly developed technique for IEF of transferrin pinpointed to an absence of 
the terminal, negatively charged sialic acid residue (Vaneijk, Vannoort et al. 
1983; Jaeken, van Eijk et al. 1984). The breakthrough provided both insight into 
the biological nature of glycosylation deficient diseases and a powerful diagnostic 
test that remains the benchmark for screening today. Isoelectric focusing and 
the measurement of serum ASA activity is still part of the metabolic screening 
program for the disease. IEF of transferrin can not only indicate the occurrence 
of CDG, but based on the IEF shift pattern, it can identify a type I or type II 
disorder. Additionally, western blot analysis and mass spectrometry of serum 
transferrin are additional screening techniques employed, but are not as 
effective. Ultimately, measurement of specific enzyme activities and genetic 
screening confirm diagnosis (type and subtype), although clinical identification of 
the disease is exceedingly difficult due to unusual and random clinical 
presentation. Even with a CDG diagnosis, a high number of biochemical 
unresolved cases, where the particular enzyme involved is unknown, (CDG-lx) 
remain problematic (Morava, Wosik et al. 2008). 
The number of identified CDG subtypes (or syndromes) is increasing 
exponentially, with most of the known subtypes having been discovered in the 
past decade. Most patients diagnosed with CDG suffer from a defective gene 
that encodes phosphomannomutase (PMM), the enzyme responsible for 
conversion of Man-6-phosphate to Man-1-phosphate. Deficiencies of PMM is the 
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basis for the most common form of CDG (type la), where the most recurrent 
mutation, R141H, has a carrier frequency of 1/60 (Kjaergaard, Schwartz et al. 
2001). The calculated frequency of homozygotes for this mutation is 1/3600, 
although there is total lack of homozygotes in the population. The expected 
homozygote R141H/R141H genotype is 45% to 60% of CDG-la patients. Those 
affected with CDG-la are compound heterozygotes for R141H. Given that 
R141H homozygotes are probably lethal, CDG-la with this genotype is a 
compelling candidate for neonatal deaths (Schollen, Kjaergaard et al. 2004). 
The second most common CDG subtype is CDG-lc with more than 20 
patients. These patients are deficient for glycosyltransferase I activity which 
adds a glucose residue to the growing LLO carbohydrate. For reasons that are 
unknown, these patients experience milder symptoms compared to CDG-la. 
Some speculate that defects that occur later in the biosynthetic pathway have a 
smaller impact on neuronal function (Eklund and Freeze 2006). The only 
treatable form of the disease is CDG-lb which is due to a deficiency in 
phosphomannose isomerase (PMI). This enzyme catalyzes the formation of 
Man-6-phospahte for fructose-6-phosphate. This enzyme is the first step in the 
A/-glycosylation pathway and defects are efficiently treatable with oral mannose 
(4 x 150 mg/kg per day). 
CDG is a rare disease with roughly 900 documented cases (Vodopiutz 
and Bodamer 2008). In addition to the infrequency of CDG, there is evidence 
suggesting a clear disequilibrium with the frequency of the disease in the 
population (Schollen, Kjaergaard et al. 2000). Two possibilities exist to explain 
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the lack of CDG patients diagnosed, either CDG illnesses are severely 
underdiagnosed or those afflicted die before birth (Matthijs, Schollen et al. 2000; 
de Lonlay, Seta et al. 2001). Although neither theory has been established, is it 
plausible that each possibility is mutually exclusive depending on the severity of 
the biosynthetic defect (i.e. type, subtype or specific genetic mutation within 
subtype). 
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Figure 6. CDG cellular location and type. CDG diseases are characterized 
as type I if the defect is located in the endoplasmic reticulum and type II if the 
defects are in the stacks of the Golgi. 
Strong losses-of-function are embryonic lethal, patients with partial losses-
of-function are occasionally born but are very ill, presenting with defects in 
virtually every body system. Individuals born with CDG are inundated with 
28 
defective glycosylation enzymes leading to absent and/or aberrant glycan 
structures (Mills, Mills et al. 2001). CDG patients suffer from psychomotor 
retardation, low muscle tone, incomplete brain development, visual problems, 
seizures, stroke-like episodes, coagulation disorders, endocrine abnormalities 
and overall failure to thrive (Freeze and Westphal 2001; Eklund and Freeze 
2006). Based on clinical features, CDG illnesses are split into two clinical 
subtypes: a neurological form and a multivisceral form with neurological 
manifestations. In spite of this, the reason why CDG patients develop neuronal 
problems is not fully known. 
Even with an identical genotype, CDG-I clinical expression varies 
considerably and ranges from very mild to extremely severe. The biosynthetic 
pathway for glycoprotein formation is relatively understood and has provided a 
basis for establishing the etiology of CDG (Jaeken and Matthijs 2001). However, 
there are still cases of CDG with unknown etiology, where strong clinical 
evidence (i.e. isoelectric focusing of serum transferrin) points to CDG but the 
defective gene has yet to be identified (Prietsch, Peters et al. 2002). As well as 
the problematic genetics factors of CDG, the mechanistic consequences of 
defective glycoprotein synthesis are very poorly understood which confounds the 
clinical identification of this disease. Incorrect or under-glycosylation is the 
underlying basis in CDG syndromes but what puzzles physicians and 
researchers is pathogenesis. Future research in CDG will emphasize structural 
elucidation of glycans at a tissue specific level and aim to alleviate the stresses 
of hypo-or aberrant glycosylate . Aside from CDG-Ib, the only treatable form of 
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the disease, supportive therapy is the only option for all other CDG conditions 
and early diagnosis is critical. 
CHAPTER 3 
C. ELEGANS AS A MODEL 
TO STUDY A/-GLYCOSYLATION 
The free-living nematode Caenorhabditis elegans is a powerful resource 
for studying complex developmental topics and provides a robust model system 
to examine various human diseases. In addition to the ease of maintenance and 
manipulability C. elegans provides, it is the most understood multicellular 
eukaryotic animal to date. The complete cell lineage has been mapped and cell 
fates remain invariant between individuals (Lambie 2002). C. elegans is a simple 
organism comprised of only 959 cells, but possess feeding, nervous, muscle and 
reproductive physiological systems found in higher eukaryotes. One of the most 
useful features of C. elegans is its susceptibility to genetic silencing. Most 
notably is RNA mediated interference (RNAi). Double stranded RNA that is 
complementary to a gene of interest can be easily directed through feeding, 
soaking or injection and results in decreased gene expression (Fire, Xu et al. 
, 1998). The use of systematic reverse genetics has increased the capacity to 
investigate functional genomics and biological functions of glycosylaton in C. 
elegans. The genome sequence of C. elegans was first published in 1998 
and contains approximately 20,000 genes (C. elegans Sequencing Consortium, 
C. e. S. 1998). More recently, the glycome of C. elegans has been studied and 
characterized. Considering the simple anatomy of C. elegans, its A/-glycan 
composition is extensive with over 100 structures present in wild-type N2 strains 
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(Paschinger, Guttemigg et al. 2008). The annotated glycome of C. elegans, in 
addition to its well characterized physiology, provides a fundamental starting 
point to compare glycan structure with biological function. 
Much of the progress in our understanding the etiology of CDG has come 
from genetic model systems, particularly S. cerevisiae and mice (Aebi and 
Hennet 2001). C. elegans share many sequence similarities to mammalian 
genes involved in the assembly, processing and modifications of a variety of 
glycans (Schachter 2004). Specifically, the early stages of A/-glycoprotein 
biosynthesis are conserved from yeast to man (Lehle, Strahl et al. 2006). 
However, the later stages of glycoconjugate synthesis are much more complex in 
vertebrates, especially mammals. C. elegans do share similarities with 
vertebrate N- and O-glycans in terms of their core structures, but the majority of 
the differences are found in molecular size and terminal elaborations. The most 
notable difference between C. elegans and higher animals is the lack of sialic 
acid in worms (Paschinger, Guttemigg et al. 2008). 
C. elegans have some biosynthetic components required for the synthesis 
of complex mammalian-type complex glycans, namely GnT-l (N-
acetylglucosamine transferase-l), GnT-ll, and GnT-V (Chen, Zhou et al. 1999; 
Chen, Tan et al. 2002; Warren, Krizus et al. 2002). Despite the identification of 
such enzymes, the presence of complex and hybrid /V-glycans are either absent 
or present at low levels in C. elegans (Cipollo, Costello et al. 2002; Natsuka, 
Adachi et al. 2002). On the other hand, the occurrence of complex glycan has 
been found at different developmental stages and may be only present to govern 
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development (Cipollo, Awad et al. 2005). Additionally, C. elegans synthesize N-
glycans having terminal fucose residues, similar to Lewis antigens found in 
humans. 
The C. elegans glycome predominately contains high-mannose (Man5. 
9GICNAC2), paucimannose (Man3.4GlcNAc2), fucose-rich (attached at the 
antennae or core), truncated complex (GICNAC3), O-methylated (O-Me) and 
phosphorlycholine (PC) substituted glycans (Haslam and Dell 2003; Cipollo, 
Awad et al. 2004; Cipollo, Awad et al. 2005; Hanneman, Rosa et al. 2006) 
(Figure 7). The most abundant class of glycans in C. elegans, and most 
eukaryotes, is the high-mannose type. This is followed by paucimannose and 
fucose-rich type structures. 
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Figure 7. C. elegans A/-glycans. From left to right are high mannose (Man6-Man9), 
fucose rich (up to 4 fucose), truncated complex (up to 3 GlcNAc) and 
paucimannose (Man3-Man4) type A/-glycans. 
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Six research groups have been involved in the analysis of the A/-glycans 
of C. elegans with mostly overlapping conclusions (Paschinger, Guttemigg et al. 
2008). Only minor amounts of truncated complex structures were found by all 
groups and PC substituted glycans were only observed in some studies. The 
disparity in the results is partly due to the method of release and the sensitivity of 
the analysis method. Some of these studies reported structures that were only 
identified in glycosylation synthesis mutants (mutants lacking mannosidase II, 
hexosaminidase and fucosyltransferase activity). Most of the 150 published N-
glycan structures represent only molecular compositions and do not consider 
structural isomers. Simply put, a hexose residue can either be a mannose, 
glucose or galactose. Additionally, a HexNAc can represent a N-
acetylglucosamine or /V-galactosamine. More common, even considering 
monomer identification, is that the structural complexity of carbohydrates is 
further complicated with different linkage possibilities that change the overall fine 
structure. Furthermore, comprehensive structural analysis is especially difficult 
due to the low amounts of many glycan compositions. 
Most investigations of A/-glycans in C. elegans use enzymes, namely 
peptide A/-glycosidase F (PNGase F) and endoglycosidase H (Endo H) for the 
release of A/-glycans. The chemical hydrazine has also been employed to 
release A/-glycans from (Natsuka, Adachi et al. 2002). With hydrazinolysis, 
hexose extensions on the 3- and 3,6-fucose positions on the penultimate and 
reducing GlcNAc residues were detected in C. elegans (Hanneman, Rosa et al. 
2006). Enzymatic release fails to liberate many A/-glycan structures in C. 
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elegans, namely fucose-rich structures (Figure 8). Complex core modifications 
include a galactose residue linked (31,4 to the core a1,6-fucose and a1,3-fucose 
on the chitobiose core (Hanneman, Rosa et al. 2006). These structures account 
for the fucose-rich type A/-glycans found in C. elegans where the majority of 
fucose residues are found at the core with some residues (up to two) at the 
terminus. Some suggest that the fucose-rich glycans in C. elegans are the 
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Figure 8. MS profiles of C. elegans A/-glycans released with 
PNGase F (top) and hydrazine (bottom). More /V-glycan peaks are 
detectable with hydrazinolysis than an enzymatic release. Adapted 
from Hanneman et. al. 2006. 
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The high-fucose content of A/-glycans is reflected by the finding of one 
core crt ,6-fucosyltransferase homologue (FUT-8), one characterized a1,2-
fucosyltransferase and five a1,3/4 fucosyltransferases in the genome 
(Paschinger, Gutternigg et al. 2008). One of the a1,3-fucosyltransferases (FUT-
1) was proven to modify the /V-glycan core, but is inhibited in the presence of the 
GlcNAc residue added by GnTI. Of the remaining four a1,3-fucosyltransferases, 
two were found to produce Lewis X structures using Gal(31,4GlcNAc-pNP as a 
substrate, whereas a third one was using a LacdiNAc structure as its receptor; 
however, FUT-4 was not active with any substrate tested (Nguyen, van Die et al. 
2007). The presence of enzymes in C. elegans with Lewis-type activities 
contrasts with the lack of Lewis-type epitopes; thus the actual role of these 
enzymes in vivo needs to be determined. 
One of the most beneficial methods of studying glycomics is to modulate 
gene expression by mutation or interference. To uncover the function of a gene, 
process or structural consequence, the use of mutants is invaluable. Using a 
mutant with a known function and comparing its glycan profile to a wild-type 
standard, aids in the definition of the biochemical functions of these genes with 
respect to the substrate specificities and their involvement in the glycosylation 
pathways. There are several examples of comparative analyses that have shed 
light on the biological function of glycosylation genes. 
The C.elegans genome contains three forms of GnTI, which is responsible 
for the addition of a (31,2-GlcNAc to the crt ,3-antenna of the chitobiose core. The 
triple-knock worm, has a normal phenotype, but fails to synthesize 31 
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paucimannose, complex and fucosylated wild-type structures (Zhu, Hanneman et 
al. 2004). This mutant only carries a maximum of two fucose residues, which 
demonstrates the GnTI dependent fucosyltransferases. 
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Figure 9. Biosynthetic glycosylation pathway in C. elegans. Green 
circle = mannose, yellow circle = galactose, red triangle = fucose, blue 
square = A/-acetylglucosamine and PC = phosphorylcholine. Adapted 
from Paschinger et. al. 2008. 
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However, five fucosylated oligomannose A/-glycan structures were present 
in the mutant, but were not in the wild-type strain, indicating the presence of 
GnTI-independent fucosyltransferases. Additionally, the absence of the o> 
mannosidase II gene (amam-2) which removes one a1,3-linked and one a1,6-
linked mannose from Man5GlcNAc2 results in non-wild-type A/-glycans 
(Paschinger, Hackl et al. 2006). As expected, the glycome of this strain lacks 
paucimannosidic truncated structures. Comparative analyses of knock-out C. 
elegans strains has provided the framework for understanding the complex 
nature and substrate specificity of glycosylation in the Golgi, little of which was 
previously known (Figure 9 ). This is only a piece of the pathway and the 
presence of more complex structures observed in higher organisms does not 
have such summarized pathways. 
The fine structures of C. elegans /V-glycans remains unresolved. Most 
published data is generally based on mass spectrometry and does not account 
for structural isomers or even glycan topology. C. elegans do not synthesize 
sialic acid residues, which distances itself from higher organisms and.may be a 
shortfall as a model. The more complex A/-glycan moieties such as Lewis x, 
fucosylated lacdiNAc, bisecting GlcNAc or tetraantennary glycans are not 
expressed in the worm. Despite the difference in complexity with mammals, our 
understanding of the role of glycoconjugates in development, disease and overall 
significance is largely due to the identification and comparative analysis of 
mutations in genes in C.elegans involved in biosynthesis. The C. elegans 
sequenced genome contains an abundance of glycosyltransferases, 
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glycosidases and lectins which highlights the potential of the worm for 
investigating basic roles of glycans in development. 
CHAPTER 4 
PROJECT AIMS 
The focus of this work will examine two aspects of CDG illnesses modeled 
in C. elegans. The first approach will explore genetic factors that may contribute 
to CDG pathology. The second portion of this study will investigate the structural 
consequences of a specific CDG type II illness. 
4.1 Genome-wide RNAi Screen to Identify Tunicamycin 
Hypersensitive Loci in C. elegans 
For any CDG type I, in which only one genetic defect is involved, there 
exists no consistent clinical manifestation. The biosynthetic pathway for 
glycoprotein formation is quite well understood and has provided a basis for 
establishing the etiology of CDG (Schollen, Kjaergaard et al. 2004). However, 
there are still cases of CDG with unknown etiology and the mechanistic 
consequences of defective glycoprotein synthesis are very poorly understood. 
Given the diversity of glycoproteins made by animals, it is likely that there are 
many diseases to which this is relevant; CDG is simply paradigmatic. In broad 
terms, clinical heterogeneity among CDG patients could have four origins. An 
individual may have inadequate genotypes in: 1) polypeptides that require 
40 
glycans for function, 2) polypeptides that require glycans for structure, 3) genes 
responsible for glycoprotein maturation (i.e. unfolded protein response, secretion 
or Golgi function, 4) genes that are involved in the lipid-linked oligosaccharide 
assembly pathway. It is plausible that an individual's genetic background may 
alter or aggravate the glycosylation defect. To explore this hypothesis, RNAi, in 
combination with a glycosylation inhibitor, will be used in a genome-wide screen 
to identify genes that make CDG worse. 
4.2 Comparative N-qlvcan Structural Analysis of the C. eleaans 
N2 (Bristol) and NF299 coac-1(k179) strains 
The second portion of this study will investigate the structure-function 
relationship of a specific CDG type II illness. Defects in the conserved oligomeric 
Golgi complex-subunit 1 (COGC-1) cause CDG-II illnesses in humans. Recently 
a C. elegans knock of the COGC-1 mammalian ortholog was made available 
through the Caenorhabditis Genetics Center. It is believed that COGC-1 defects 
compromise the function of the Golgi and trigger incorrect glycan assembly. This 
strain will enable comprehensive glycan comparative analysis of a CDG-
ll/COGC-1 state verses a wild-type condition via mass spectrometry. The work 
will analyze the implications of defective glycosylation machinery and will seek to 
relate Golgi function to aberrant glycan structures. The overall goal is to 
determine glycosylation trends in CDG-II/ COGC-1 type conditions modeled in C. 
elegans. Structural analysis of the COG complex defective C. elegans strain will 
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help in understanding the molecular basis of CDG and other glycosylation-
dependent diseases. 
CHAPTER 5 
GENOME-WIDE RNAi SCREEN TO IDENTIFY TUNICAMYCIN 
HYPERSENSITIVE LOCI IN C. ELEGANS 
Protein A/-glycosylation is an essential and pervasive event in eukaryotic 
development. Mild defects in this process lead to deficiencies in cellular growth 
and function and are associated with disease. Most notable are a group of 
inherited autosomal recessive human disorders called Congenital Disorders of 
Glycosylation (CDG). CDGs are categorized as type I or type II depending on 
the location in the biochemical pathway where the defect occurs. Type I 
disorders are characterized as defects of enzymes in the lipid-linked 
oligosaccharide assembly pathway. Currently there are 12 known defects, or 
subtypes, in this category. Type II disorders are deficiencies of enzymes 
involved in the trimming and processing of the protein bound oligosaccharide. To 
date there are eight defective enzymes within type II CDGs (Jaeken and Matthijs 
2007; Zeevaert, Foulquier et at. 2008). 
CDG is a rare disease with roughly 900 documented cases (Vodopiutz 
and Bodamer 2008). In addition to the infrequency of CDG, there is evidence 
suggesting a clear disequilibrium with the frequency of the disease in the 
population (Schollen, Kjaergaard et al. 2000). Two possibilities exist to explain 
the lack of CDG patients, either CDG illnesses are severely underdiagnosed or 
those afflicted die before birth (Matthijs, Schollen et al. 2000; de Lonlay, Seta et 
al. 2001). Although neither theory has been established, is it plausible that each 
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possibility is mutually exclusive depending on the severity of the biosynthetic 
defect (i.e. type, subtype or specific genetic mutation within subtype). 
Individuals born with CDG are inundated with defective glycosylation 
enzymes leading to absent and/or aberrant glycan structures (Mills, Mills et al. 
2001). CDG patients suffer from psychomotor retardation, low muscle tone, 
incomplete brain development, visual problems, seizures, stroke-like episodes, 
coagulation disorders, endocrine abnormalities and overall failure to thrive 
(Eklund and Freeze 2006). The biosynthetic pathway for glycoprotein formation 
is quite well understood and has provided a basis for establishing the etiology of 
CDG (Jaeken and Matthijs 2001) (Figure 10). However, there are still cases of 
CDG with unknown etiology, where strong evidence points to CDG but the 
defective gene has yet to be identified (Prietsch, Peters et al. 2002). As well as 
the problematic genetics factors of CDG, the mechanistic consequences of 
defective glycoprotein synthesis are very poorly understood which confounds the 
clinical identification of this disease. 
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Figure 10. Lipid-linked oligosaccharide pathway in the endoplasmic 
reticulum. CDG type diseases are illustrated. S. cerevisiae homologues are 
also shown (alg: asparagine-linked glycosylation). 
Since all CDG-I etiologies alter the effectiveness and substrate availability 
of oligosaccharyltransferases, it might be expected that the disease would 
manifest itself consistently from patient to patient. This is not the case, as clinical 
CDG symptoms within types and subtypes vary considerably between individuals 
making diagnosis difficult. Additionally, in any specific CDG illness, where the 
genetic mutation is the same, no consistent clinical manifestation exists and the 
severity of the illness ranges from very mild to severe (Aebi and Hennet 2001). 
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Given the ubiquity of glycoproteins and the ability of /V-glycans to modulate 
protein function, it would seem likely that defects in glycosylation would lead to 
diverse and pleiotropic phenotypes, such as the multisystemic syndromes 
associated with CDG-I. Since glycoprotein oligosaccharides can only exert their 
effects in the context of the polypeptide to which they are attached, variation in 
the glycoprotein polypeptide gene in outbred populations could interact with a 
CDG-I etiology to modify the consequences for specific glycoproteins. This 
collectively could trigger the broad clinical spectrum seen in an individual patient. 
To date clinical evidence fails to explain the exceeding inconsistency between 
the etiology and pathology in all CDG conditions. 
It is plausible that an individual's genetic background may alter or 
aggravate a CDG glycosylation defect. Given the diversity of glycoproteins made 
by eukaryotes and the extent of A/-glycosylation, additional biochemical defects 
directly or indirectly involved with a glycosylation defect could elicit variable 
phenotypes characteristic of CDG diseases. For example, the clinical severity of 
CDG-la, caused by phosphomannomutase deficiency, is enhanced by a defect in 
a1,3-glucosyltransferase, an enzyme also found in the lipid-linked 
oligosaccharide (LLO) pathway (Westphal, Kjaergaard et al. 2002). Defects in 
a1,3-glucosyltransferase alone result in CDG-lc illnesses. In addition to this 
example, previous reports allude to the possibility of genetic and/or 
environmental factors that contribute to the clinical spectrum observed in CDG-I 
patients (Freeze and Westphal 2001). 
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In broad terms, clinical heterogeneity among CDG patients could have 
four origins. An individual may have mutations in genes encoding: 1) 
polypeptides that require /V-glycans for function, 2) polypeptides that require N-
glycans for structure, 3) genes responsible for glycoprotein maturation (i.e. 
unfolded protein response, secretion or Golgi function), 4) genes that are 
involved in the lipid-linked oligosaccharide assembly pathway (Figure 11). Of the 
four theoretical types of mutations, two fall in the "effector" category, where the 
protein component of a glycoprotein is not synthesized correctly. A third, or 
"etiologic" type, are flawed loci that result in defective glycosylation machinery 
(i.e. CDG-type mutations). The fourth, or "maturation" type, are gene products 
responsible for secretion and quality control of immature glycoproteins. Any 
individual with CDG may have additional genetic defects anywhere in their 
genome that rely on A/-linked glycosylation to function correctly. It is this 
interaction between the CDG glycosylation defect and a secondary genetic 
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Figure 11. /V-glycosylation pathway from synthesis to localization. Plausible 
interactions that enhance defects in LLO biosynthesis that cause CDG I diseases to 
fall into three categories based on their role in /V-glycosylation. 
In this study genetic factors that influence CDG pathogenesis are 
explored. The notion is that for any cellular function that depends on N-
glycosylation, a protein component must be involved (the underlying polypeptide 
of a glycoprotein, a lectin receptor etc). Because so many structures and 
functions are compromised in /V-glycosylation diseases, the gene products that 
contribute to lethality or particular symptoms cannot be resolved. This 
experiment demonstrates a novel approach that combines RNA mediated 
interference (RNAi) in combination with a /V-glycosylation inhibitor to 
systematically dissect this problem on a gene-by-gene basis. 
Much of the progress in understanding the etiology of CDG-I has come 
from genetic model systems, particularly S. cervisiae and mouse (Aebi and 
Hennet 2001). By exploiting C. elegans' susceptibility to genetic silencing, it is 
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possible to conduct a genome-wide RNAi screen to identify genes that are 
dependant upon A/-linked glycosylation. 
To accomplish this, a sub-phenotypic dose of the nucleoside antibiotic 
tunicamycin was used to mimic a very mild CDG-l-like condition by partially 
inhibiting the first step in the LLO pathway. Tunicamycin inhibits the action of the 
UDP-GlcNAc dolichol-phosphate A/-acetylglucosamine 1-phosphate transferase 
(DPAGT1) in the first step of the lipid-linked oligosaccharide biosynthetic 
pathway (Zhu, Zeng et al. 1992). Deficiencies of this enzyme in humans cause 
CDG-lj illnesses. CDG-lj is caused by hypomorphic mutations in the human 
ALG7 gene, which is conserved in eukaryotes and encodes the enzyme 
responsible for dolichol pyrophosphate /V-acetylglucosamine formation (Barnes, 
Hansen et al. 1984; Wu, Rush et al. 2003). Patients diagnosed with CDG-lj 
suffer from severe developmental delays, hypotonia, seizures, microcephaly, 
exotropia and death. Without this reaction, no donor for 
oligosaccharyltransferase can be formed and protein A/-glycosylation is absent. 
In addition to tunicamycin treatment, the expression of an individual 
glycan-dependant protein was decreased via RNAi, which will render it 
hypersensitive to reduced glycosylation. Because this interaction is largely 
specific, glycan-dependant gene products can be identified. Under these 
conditions, it is assumed that gene-products that control glycosylation efficiency 
or glycoprotein maturation, or encode key glycoproteins that require glycosylation 
for their synthesis or activity, will manifest synthetic enhancer or suppressor 
phenotypes. The genome-wide RNAi screen with the ORFeome v1.1 library and 
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its analysis in silico have revealed 512 tunicamycin-hypersensitive loci, some of 
which are characterized and cloned but not previously recognized to be N-
glycosylation dependent. 
5.1 Materials and Methods 
The C. elegans strains NL2099 rrf-3 (pk1426), VC569 tag-179 (ok809), 
RE666 ire-1 (v33) and N2 (Bristol) were obtained from the Caenorhabditis 
Genetics Center, University of Minnesota, USA. General methods used for 
cultivating, handling and genetic manipulation of C. elegans are as described 
(Brenner 1974). Genome-wide RNAi screening protocols were performed by 
feeding in NL2099 rrf-3 (pk1426), with minor adaptations from previous works 
(Simmer, Moorman et al. 2003). The ORFeome v1.1 RNAi library was supplied 
from the Vidal lab at the Dana Farber Caner Institute (Reboul, Vaglio et al. 2003; 
Rual, Ceron et al. 2004). Tunicamycin (Calbiochem) was dissolved in DMSO to 
50 mg/ml stock concentration. To obtain synchronous populations of larval stage 
1 hatchlings, eggs were acquired by digesting populations containing gravid 
hermaphrodites with alkaline hypochlorite and washing the egg pellet three times 
by centrifugation with M9 buffer (Hope 1999). Eggs hatched overnight in M9 
buffer or were transferred to 35mm petri dishes. C.elegans strains were 
cultivated at 20°C unless otherwise indicated. Observations were made using a 
Leica MS 5 stereomicroscope at 10x-40x magnification (Leica Microsystems). 
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To establish the effect of tunicamycin on larval lethality, individual 
hatchlings (n=144) were placed in each well of a 24-well cluster plate containing 
NGM supplemented with tunicamycin (0-10 ug/ml). On day three and day six, 
plates were scored for death (no pumping, twitching or movement when prodded 
with platinum wire) of the founder hermaphrodite or the appearance of hatched 
progeny. 
The larval phenotype assay was performed following synchronization via 
egg prep. 15 u l of hatchlings (-200 L1 Larvae) in buffer solution were pipetted 
onto seeded 60mm NGM plates containing 0-5 ug/ml tunicamycin. Animals were 
counted and phenotypes were scored after three days. 
Similarly to the larval lethality assay of N2, separate populations of 
NL2099 rrf-3 (pk1426), RE666 ire-1 {v33), VC569 tag-179 {ok809) and N2 
(Bristol) were tested in increasing concentrations of tunicamycin. Each strains 
was synchronized by alkaline hypochlorite egg prep method. 5 ul of hatchings 
(-150 L1 Larvae) in M9 buffer were placed on 35mm Petri dishes containing 0-10 
|ag/ml tunicamycin. Animal survival was scored based on the ability of larvae to 
reach gravid hermaphrodites after three days. 
All RNAi was performed as observed by Simmer, Moorman et al. The 
ORFeome v1.1 library of recombinant E. co//strains, consisting of 11,942 
constructs, was arrayed in microtiter plates stored at -80°C. Bacteria were 
cultured in 2xYT containing 50 ug/ml ampicillin and 12.5 u.g/ml tetracycline for 72 
hours at 22°C to ensure the presence of the plasmid (ampicillin selection) and the 
DE3 lysogen carrying the IPTG inducible T7 RNA polymerase (tetracycline 
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selection). From these, 50 uL liquid cultures were grown overnight in 2xYT 
supplemented with 50 u,g/ml ampicillin at 37°C with shaking. 15 uL aliquots of 
the overnight culture were used to grow bacterial lawns on 24-well clusters of 
NGM supplemented with 50 u,g/ml ampicillin and 1mM IPTG and 2 u,g/ml 
tunicamycin. These cultures were grown at room temperature for 48 hours to 
create a bacterial food source expressing double-stranded RNA. 
In both phases of the screen, 24 well clusters were used as the platform 
for C. elegans analysis. Each column, consisting of 4 wells, consists of one 
RNAi gene. In this manner, each gene tested provides four observable wells. 
Initially, 7 to 10 NL2099 rrf-3 (pk1426) animals were placed in the top row of 
each plate to generate progeny that have only existed in the presence of each 
RNAi construct and 2 u.g/ml tunicamycin. After two days of "priming", a single 
gravid hermaphrodite from the top row was transferred to each of the other lawns 
and allowed to produce F1 progeny. During the triage screen, genes where at 
least two of the three replicates displayed concordant phenotypes were regarded 
as candidates. Any phenotypes observed in the 'priming' well were also scored 
and data collected was weighed with lesser significance when selecting phase II 
candidates. Phenotypes in the three remaining wells, including P0 and Fi 
progeny, were given a value of 10. Phenotypes in the "priming" well was marked 
a value of 5. 
For the genome-wide screen the preparation of media and bacterial 
culture were followed as stated previously. 24 well cluster plates were used for 
both the triage and follow-up screens (phase I & II). Each cluster yielded results 
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for 6 genes. Every column corresponded to a specific RNAi gene (4 wells total). 
7 to 10 larval stage 3 NL2099 rrf-3(pk1426) animals were plated by hand to each 
well in the top row of each cluster. After 48 hours at 15°C to "prime" these 
parents, single gravid hermaphrodites were transferred to each of the three 
replicate wells in the column and allowed to segregate progeny at 22°C for 72 
hours. All wells were scored for any visible phenotypes in P0 and F-i generations 
and noted using a controlled vocabulary. 
5.2 Results 
The phenotypic consequences of a CDG-l-like defect were characterized 
in C. elegans using 0, 3 and 5 u.g/ml tunicamycin (Table 3). Like CDG-I in 
humans, tunicamycin treatment in C. elegans results in a pleiotropic phenotype. 
In the complete absence of tunicamycin, nearly all animals reach adulthood and 
exhibit no aberrant phenotype. At 3 (ig/ml concentration, the consequences of 
tunicamycin treatment become more evident. Only -76% of the population is 
wild type and reach the adult stage. Nearly 10% of the larvae die. Interesting to 
note is the range of phenotypes present with the mild dose of drug; characteristic 
of CDG-I diseases. When the tunicamycin concentration is increased to 5 ng/ml 
almost all animals remain in the larval stage, of which -75% are lethal. Only 1% 






























































Table 3. Tunicamycin incudes a pleotropic condition in C. elegans. Tunicamycin 
concentrations are directly correlated with an increase in observable phenotypes and 
longevity. Tunicamycin concentrations at 3 u,g/ml trigger a wide variety of phenotypes 
among N2 adults and larvae, emulating a CDG-l-like pathology. Concentrations at 
5u.g/ml and above result predominantly in lethality. 
(Clr, clear patches; Dpy, dumpy; Egl, egg-laying defective; Gro, slow growth; Let, 
lethality; Pvl, protruding vulva; Sck, sick; Sma, small; Unc, uncoordinated locomotion; 
Vab, variably abnormal morphology; W.T., wild type.) 
The success of the genome-wide RNAi screen relies on a low dose of the 
antibiotic tunicamycin to emulate a mild form of CDG type Ij. In C. elegans high 
doses of tunicamycin cause adult and embryonic lethality, but partial inhibition by 
lower doses results in a variable phenotype. Tunicamycin at a concentration of 2 
ug/ml or less does not significantly affect larval development, but at greater 
concentrations survival rates decrease (Figure 12). However, the presence of 2 
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|jg/ml tunicamycin emulates a lesser "sub-phenotypic" form of CDG-lj in C. 
elegans. 
0 1 2 3 4 5 6 7 8 9 10 
Tunicamycin (ng/ml) 
Figure 12. Tunicamycin induces a dose-dependant lethality in the 
N2 C. elegans strain. 
Tunicamycin dose-dependent lethality in C. elegans can vary from one 
mutant strain to another (Figure 13). Four strains were grown in the presence of 
increasing concentrations of tunicamycin. The four test-strains included: 1) N2 
(Bristol) wild-type strain, 2) VC569 tag-179 (ok809) which is a complete loss of 
function of glucosyltransferase activity required to add the terminal glucose to the 
LLO formed in the endoplasmic reticulum, 3) RE666 ire-1 (v33) which is required 
for the unfolded protein response (UPR) that can be caused by incomplete 
glycosylation of proteins and result in their accumulation in the endoplasmic 
reticulum, 4) NL2099 rrf-3 (pk1426) which encodes an RNA-directed RNA 
polymerase that inhibits somatic RNAi and renders C. elegans hypersensitive to 
55 
RNAi gene knockdown. The C. elegans VC569 strain is exceedingly sensitive to 
tunicamycin possibly due to a decrease in substrate availability caused by 
blockage of DPAGT1 in the ER. Additionally, the strain RE666 is more sensitive 
to tunicamycin than N2 (Bristol) or NL2099 rrf-3(pk1426) strains. Elevated 
concentrations of tunicamycin can trigger the UPR and is evident in this assay 
(Iwata and Koizumi 2005). Since the NL2099 strain was used in the genome-
wide screen, it is necessary to note that the effect of 2 |ig/ml tunicamycin 
between N2 and NL2099 is comparatively minor. 
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Figure 13. Tunicamycin affects postembryonic development among C. elegans 
strains. The percent of animals that reach fertile adulthood (% gH) were measuered 
as a function of tunicamycin concentration. 
A series of RNAi trials were conducted to validate the legitimacy of the 
screen and the existence of tunicamycin-hypersensitive loci. Based on previous 
studies, a small number of genes that were either known or suspected to be 
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hypersensitive to tunicamycin were assayed on 2 pg/ml tunicamycin (Shen, Ellis 
et al. 2001). These included 6 "etiologic" genes in-the LLO pathway (Table 4) 
and 6 "maturation" genes in endoplasmic reticulum-Golgi functions (Table 5). To 
substantiate tunicamycin hypersensitivity of both genotypes, genes from the ER 
luminal phase of the LLO pathway and various genes in secretion were knocked-







































Table 4. RNAi of LLO genes with 2pg/ml tunicamycin. RNAi of loci in the LLO 
pathway presents no overt phenotype on NGM alone. In the presence of 2 ug/ml 
tunicamycin, RNAi silencing of etiologic genotypes enhances hypo-glycosylation 
that causes multiple phenotypes. Corresponding RNAi phenotype experiments 
from WormBase were are also shown for comparison. 
Our results were also compared to previously described RNAi phenotypes 
with an rrf-3(pk1426) mutant background of the same genes annotated in 
WormBase (http://www.wormbase.org). All RNAi phenotypes tested correlated 
with previous works except in the case of sequence name C08H9.3 which 
encodes the glucosyltransferase responsible for the second glucose addition on 
the N2M9Gi LLO precursor (Rual, Ceron et al. 2004). RNAi phenotypes in our 
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hands produced a slow growth phenotype, whereas previous reports found larval 
arrest, embryonic lethality and reduced brood size. Additionally, K09E4.2 
generated a "Gro" RNAi phenotype in the absence of tunicamycin. Published 
reports found no observable phenotype via RNAi (Kamath, Fraser et al. 2003; 
Rual, Ceron et al. 2004). However, the slow growth phenotype was enhanced to 
embryonic lethal in the presence of 2 u.g/ml tunicamycin. 
To verify the "maturation" hypothesis, trials with RNAi library plasmids 
representing all suspected and known tunicamycin-hypersensitive loci were 
tested (Table 5). Once again, results were consistent with those made by others 
with the exception of sel-9 which gave no phenotype in the absence of 
tunicamycin. By and large the RNAi assays were consistent with published 
results and also demonstrate a 10-30% replication variability of the genes tested 
which is common among laboratory-to-laboratory RNAi experiments in C. 















































Table 5. RNAi of "maturation" genes with 2ug/ml tunicamycin. RNAi 
silencing of genes involved in three aspects of ER-Golgi networking exhibit no 
phenotype on NGM alone. However in the presence of 2 ug/ml tunicamycin, 
synthetic effects are evident in a range of phenotypes. ERAD = ER associated 
degradation, UPR = unfolded protein response and GVT = Golgi vesicle 
trafficking. 
These tests establish that RNAi, in combination with a low dose of 
tunicamycin, can generate synthetic phenotypes to identify genes that are 
tunicamycin hypersensitive. All of the above genes were included as positive 
controls in the genome-wide screen and at the culmination of the screen 8 of 12 
control genes remained present in the final results. 
Moreover, we cannot exclude the possibility that 2 u.g/ml tunicamycin 
causes a generalized increase in the effectiveness of the RNAi by feeding 
method. It is important to show that the presence of tunicamycin does not alter 
the effectiveness of RNAi, or a significant number of genes that control visible 
phenotypes (particularly neuronal ones) that are refractory to RNAi will become 
obvious as screen results are generated. If this was the case, then our approach 
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would result in numerous false positives. To exclude this possibility, loci known 
to be refractory to RNAi (i.e. genes localized to neuronal cells) and that have 
observable mutant phenotypes were tested on 2 u.g/ml tunicamycin (Asikainen, 
Vartiainen et al. 2005). It is expected that the RNAi phenotype of each locus 
would be unaltered by drug treatment. These results proved the legitimacy of the 
screen showing that tunicamycin-hypersensitive genes can be identified in the 









































Table 6. Tunicamycin treatment does not alter RNAi effectiveness in C. 
elegans. Seven C. elegans strains that exhibit both a mutant phenotype and 
wild-type RNAi phenotype were chosen to test RNAi in the presence of 
tunicamycin. All strains remained refractory to RNAi when tunicamycin was 
present, demonstrating that tunicamycin does not modify the efficiency of RNAi. 
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The genome-wide screen required strict criteria for candidate selection for 
the second phase to limit the accumulation of false positives. A set of 100 genes 
that gave rise to phenotypes in 0,1,2,3 and 4 observatory wells out of 4 in the 
triage screen were tested in the presence and absence of 2 ng/ml tunicamycin 
(n=500 total genes tested). 
The penetrance was assessed by subtracting the number of wells showing 
any phenotype(s) with tunicamycin from the number in its absence (A). The 
larger the value of A, the more dependent the phenotype penetrance is on 
tunicamycin; i.e. a locus that induced phenotypes in all 4 wells containing 
tunicamycin but none in its absence would have A=4. The delta values were 
plotted against the percent total in each of the 5 sets (100 genes per set) tested. 
The effect of expressivity was assessed similarly except that A is 
calculated using the number of wells showing non-viable phenotypes under each 
condition. In this case, the larger value of A, the more severe the phenotype 
becomes when tunicamycin is present; i.e. a locus that induced a "dumpy" 
phenotype in all 4 wells in the absence of tunicamycin but "lethal" in all wells 
when drug was present would have A=4. Under this analysis, false positives and 
loci causing single-gene phenotypes score A=0, but those genes that are 
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Figure 14. Calculation of phenotype penetrance and expressivity. These 
graphs represent the criteria for genes that were retested in the second phase of 
the genome-wide screen. Delta values were calculated by subtracting the 
number of wells showing any phenotype (penetrance) and wells showing non-
viable phenotypes from the number in its absence. For penetrance, the larger 
delta values correspond to a greater dependence of the phenotype penetrance on 
tunicamycin. For expressivity, the larger the delta values correspond to an 
increase in phenotype severity when tunicamycin is present. 
Loci causing phenotypes in <1 well during the triage screen behave 
randomly during retesting and the group results fitted to a Gaussian curve 
centered on 0 as expected. However, loci that caused phenotypes in >2 wells 
during the triage screen behaved non-randomly in the second round with a 
substantial fraction scoring A>2 which was two standard deviations from the 
mean and represented tunicamycin-hypersensitive loci. 
The genome-wide RNAi screen was divided into two phases: 1) a triage 
screen of the ORFeome v1.1 RNAi library for all genes that cause a visible 
synthetic phenotype in the presence of 2 u,g/ml tunicamycin and 2) a follow-up 
screen where candidate genes are retested in the presence and absence of 2 
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|ig/ml tunicamycin to separate tunicamycin-hypersensitive loci from single-gene 
phenotypes and false positives. During the triage screen, criterion for selecting 
candidates for progression to the second phase was experimentally established 
(i.e. phenotypes in 2 or more wells out of 4). 
The completion of the phase I triage screen required 13,190 RNAi assays 
in the presence of 2 u.g/ml tunicamycin. Of those genes tested in phase I, 4,459 
genes were candidates for the phase II follow-up screen based on the criteria 
mentioned above. Ultimately, 512 genes were found to be tunicamycin-
hypersensitive. These results were further analyzed to determine function 
location and presence of Asn-X-Ser/Thr sequon for /V-linked glycosylation (see 
Discussion & Supplementary Data). Additionally, qualified results were classified 
according to their eukaryotic orthologous group (KOG) assignments to determine 
cellular functions (see Discussion). 
5.3 Discussion 
The core of this analysis is that mutations in "etiologic", "maturation" or 
"effector" loci will interact genetically and that this interaction is the basis of the 
clinical diversity and heterogeneity in CDG-I. Much of the progress in 
understanding the etiology of CDG-I has come from genetic model systems, 
particularity S. cerevisiae and mouse (Aebi and Hennet 2001). By utilizing RNAi 
silencing in C. elegans, we can identify tunicamycin-hypersensitive loci, 
effectively asking what genes enhance the severity of a CDG-I condition? The 
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widespread understanding of C. elegans and its' susceptibility to genetic 
silencing it enables the investigation of functional glycomics and allows us to 
systematically investigate CDG interactions on a gene-by-gene basis. Overall, 
each gene that was determined to be hypersensitive was tested at least three 
times; two assays with tunicamycin and one without. A list of 512 genes was 
found to be decidedly tunicamycin-hypersensitive. 
It is also important to consider that some tunicamycin-hypersensitive 
genes may be involved in drug metabolism or and not directly interrelated with N-
glycosylation. Effectively, knocking down these genes may increase the 
absorption or decrease detoxification of tunicamycin and will result in an 
increased drug effect. However, the quality of this experiment relies on precise 
drug treatment and only in the absence of drug can this possibility be excluded. 
That is to say future experiments would include a double mutant containing both 
the RNAi sensentive rrf-3(pk1426) mutant background with an additional loss-of-
function mutation in the LLO pathway, thereby effectively replacing drug 
treatment with a genetic condition. 
Currently it is difficult to characterize each gene into its respective 
functional class, but some results can be drawn from previous works. This study 
cannot definitively prove the assignment of specific genes to particular functions 
without confirmatory follow up. However this screen does provide researchers 
with a list of potential genes that could be used to screen human CDG patients in 
hopes of identifying enhancer loci that contribute to the severity of the CDG-I 
diseases. 
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Furthermore, results were evaluated by comparing our results to 
eukaryotic orthologous groups of proteins (KOGs) from sequenced genomes 
(Tatusov, Fedorova et al. 2003). This analysis classified our tunicamycin-
hypersensitive genes into functional protein sets. Of the 512 tunicamycin-
hypersensitive genes confirmed, 308 had KOG assignments and as a result 204 
were omitted from analysis (Figure 15). The two largest known groups of KOG 
protein sets in our results were involved in translation, ribosomal structure and 
biogenesis (n=49) and signal transduction mechanisms (n=33). Unsurprisingly, 
the subsequent two groups were posttranslational modification, protein turnover, 
chaperones (n=27) and intracellular trafficking, secretion, and vesicular transport 
(n=20). Unfortunately, almost two-thirds of the results are uncharacterized and 
have no known function. This analysis helps to reasonably classify results in 
"effector", "maturation" or "etiologic" gene classes. 
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Translation, ribosomal structure and biogenesis jHaaaaaaHaHHHaBHaaMBHMBHaai 49 
Transcription • • • • • • • • i 18 
Signal transduction mechanisms ( • • • • • • • • • • • • • • • • 33 
Secondary metabolites biosynthesis, transport and catabolism • 1 
Replication, recombination and repair • • • • • 9 
RNA processing and modification • • • • • • • • • i 18 
Posttranslational modification, protein turnover, chaperones ( • • • • • • • • • • • • 27 
Nucleotide transport and metabolism Mi 3 
Nuclear structure • 1 
Lipid transport and metabolism ! • • • • 8 
Intracellular trafficking, secretion, and vesicular transport P B M H B M H B I 20 
Inorganic ion transport and metabolism pm 4 
General function predictions only wmmmmmmmmmmmmmmmm 37 
Function unknown 
Extracellular structures mmm 7 
Energy production and conversion 
Defense mechanisms • • • 5 
Cytoskeleton p a M 7 
Coenzyme transport and metabolism an 3 
Chromatin structure and metabolism • • • 6 
Cell wall/membrane/envelope biogenesis m» 3 
Cell cycle control, cell division, chromosome partitioning • • • • • 10 
Carbohydrate transport and metabolism • • 4 
Amino acid transport and metabolism • 2 
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Figure 15. RNAi gene assignments via KOG analysis. Analysis of 
eukaryotic orthologous groups (KOGs) classify tunicamycin hypersensitive 
genes into functional sets. Of 512 genes found to be hypersensitive, 308 
had KOG assignments. 
In addition to KOG analysis, cellular location was determined with 
Proteome Analyst (http://path-a.cs.ualberta.ca), a web based tool that can 
analyze the function and subcellular location of each sequence based on 
BLASTS for sequence alignment. Brief identifications and/or concise descriptions 
of each gene product were annotated manually with the aid of WormBase. 
Results were also examined with NetNglyc 
(http://www.cbs.dtu.dk/services/NetNGIyc), an online server that predicts N-
glycosylation sites in proteins using artificial networks that examine the sequence 
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context of Asn-Xaa-Ser/Thr sequons supplied in FASTA format (supplementary 
data). 
As mentioned above results were expected to fall into three categories; 
"effector", "etiologic" and "maturation". "Effector" gene products can be further 
classified into two subclasses. "Formation" subclass members require N-
glycosylation to fold, pass quality control or to be trafficked within the cell. Those 
in the "function" subclass require A/-glycosylation for their extracellular function; 
their catalytic, ligand-receptor, localization or stability properties are modulated 
by the presence and structure of the glycans. Again stating whether the glycan 
function is a structural or functional role is not possible at this point, but these two 
subclasses can be assessed when examined together. 
There are several examples of "effector" class genes found in the results. 
The gene, eff-1 (epithelial fusion failure), is a known type I transmembrane 
glycoprotein required for epithelial cell fusion (Mohler, Shemer et al. 2002). RNAi 
knock-down of eff-1 in the presence of 2 u.g/ml tunicamycin caused larval arrest, 
sterility, uncoordinated movement, slow growth and clear phenotypes. RNAi 
treatment in the absence of tunicamycin remained wild-type phenotypes. A 
second "effector" type result is the mom-2 (more mesoderm) gene which is a 
member of the Wnt family of secreted signaling glycoproteins. In addition to 
being a glycoprotein, MOM-2 may also function as a ligand in Wnt signaling 
during embryonic development to specify the production of endoderm cells in the 
gut (Thorpe, Schlesinger et al. 2000). Gene knock-down of mom-2 with 
tunicamycin generates embryonic lethality, small brood size and sick 
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phenotypes. In the absence of tunicamycin, the mom-2 RNAi phenotype is wild-
type. 
The less-than expected amount of "etiologic" class genes in the results 
may be due to a general reduction in the number of possible candidate genes 
present in the C. elegans genome or their absence in the ORFeome v1.1 RNAi 
library. There are 17 genes in the C. elegans genome that correspond to 
enzymes in LLO biosynthesis (Berninsone 2006). Of those 17 genes, 11 are 
present in the RNAi library. 4 genes of 11 were found to be tunicamycin-
hypersensitive and 2 genes produced robust phenotypes with and without drug. 
Only 4 of the 11 genes failed to qualify from the phase I triage screen, which is 
well within the false negative rate that is typical in genome-wide RNAi screens 
(Kamath, Fraser et al. 2003; Simmer, Moorman et al. 2003). 
In addition to the 17 genes mentioned above, 4 genes were identified in 
the screen that are involved directly in /V-linked glycosylation and not part of LLO 
biosynthesis. One such result is the gene T09A5.11, which encodes a 48 kD 
subunit of the oligosacchyltransferase complex responsible for the en bloc 
transfer of the LLO oligosaccharide to nascent polypeptides in the endoplasmic 
reticulum. The RNAi phenotype of this gene knock-down was identical in the 
presence and absence of tunicamycin. However when drug was present, the 
expressivity of the embryonic lethality phenotype increased from 25% to 75%. 
The other 3 genes found to be tunicamycin-hypersensitive in the final results 
encode 2 mannosyltransferases and 1 glucosyltransferase that are found in LLO 
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biosynthesis. Moreover, an additional UDP-glucosyltransferase was identified 
that may also act in LLO biosynthesis. 
"Maturation" gene classifications, defined by genes in ER-Golgi maturation 
and secretion, were highly abundant in the 512 gene results based on KOG 
analysis. The phenotype penetrance caused by tunicamycin on the s/f (surface 
antigenicity abnormal) RNAi control experiments demonstrates that maturation of 
nascent glycoproteins can influence the phenotype outcome of defects in N-
glycosylation in C. elegans. Likewise, many lectins may act in intracellular 
systems necessary for the transport of immature glycoproteins through the ER-
Golgi secretory pathway. Additionally, components of the Golgi glycosylation 
machinery responsible for the redistribution and proper localization of 
glycosylation enzymes were found in the results. For example, a subunit of the 
coatamer complex protein (COPI) which is involved in retrograde transport of 
Golgi enzymes was found to be hypersensitive to tunicamycin. RNAi of this gene 
in the presence of tunicamycin caused phenotypes in all 4 observable wells 
whereas in the absence of drug, only phenotypes in 2 wells were scored. 
A second example tunicamycin-hypersensitivity in Golgi trafficking was 
found in the SNAP-25 (synaptosome-associated protein) component of the 
SNARE complex. The SNARE complex mediates fusion of Golgi transport 
vesicles and may interact with COPI vesicles directly during intercistemal Golgi 
transport (Ungar, Oka et al. 2006). RNAi of the SNAP-25 component with 
tunicamycin caused embryonic lethality and sterile progeny and produced no 
phenotypes in the absence of drug treatment. 
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Currently the remarkable variability of CDG diseases is generally believed 
to be a consequence of insufficient glycosylation among many glycoproteins in 
different cells. In this study evidence shows that variable pathology may also be 
caused by interaction between the primary CDG-I etiologic defect and modifier 
loci in the genetic background. Also this is a demonstration of a novel approach 
that systematically dissects the complex glycosylation phenotype into specific 
glycan-dependent proteins and functions. As a result the conserved 
mechanisms that underlie the type of pathology observed in type I congenital 
disorders of glycosylation and identify genes that contribute to the severity of the 
disease are successfully delineated. 
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CHAPTER 6 
COMPARATIVE A/-GLYCAN STRUCTURAL ANALYSIS OF THE C. ELEGANS 
N2 (BRISTOL) AND NF299 cogc-1(k179) STRAINS 
The Golgi apparatus serves not only as the hub of the secretory pathway, 
but is vital in the glycosylation and trafficking of glycoproteins, glycolipids and 
proteoglycans. Glycosylation of proteins in the Golgi accounts for the 
diversification of AMinked glycans and the synthesis of O-linked glycans. 
Transcriptional control of glycosylation enzymes involved in synthesis, 
modification and catabolism are believed to be the driving force in glycan 
diversity and abundance (Nairn, York et al. 2008). However, these studies only 
confirm the major glycoforms and simply confirm the correlation between glycan 
structures and the transcripts that encode the relevant enzymes. The fine details 
and changes in glycan structure cannot be accounted for by transcriptional 
regulation of glycosyltransferases or glycosidases alone. It is known that 
sequential modifications of glycoproteins by glycosyltransferases also depends 
on the precise nonuniform steady-state distribution of resident glycosylation 
enzymes within the Golgi (Ungar, Oka et al. 2006). 
Over thirty years ago Whaley stated, "No cellular organelle has been the 
subject of as many, as long lasting or as diverse polemics as the Golgi 
apparatus" (Whaley 1975). Still this intracellular membrane stack remains an 
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enigma and how proteins traverse through this pathway remains to be answered. 
As discussed in Chapter 1, two models of Golgi morphology exist, both of which 
depend on the localization of glycosidases, glycosyltransferases and other 
resident proteins. In both cases, the Golgi membrane system undergoes 
continuous changes but its influence on glycan structure is uncertain 
(Shestakova, Zolov et al. 2006). The various cistemae of the Golgi maintain 
different balances of enzymes and transporters amid constant movement of 
incoming and maturing cargo. Responsible for the movement of cargo vesicles 
are a group of multisubunit protein assemblies termed 'tethering complexes' 
(Munson and Hughson 2002; Whyte and Munro 2002; Dong, Hutagalung et al. 
2005). Among these complexes is the Conserved Oligomeric Golgi complex 
(COG), what is strongly implicated in retrograde trafficking of COP I vesicles 
within the Golgi (Cavanaugh, Chen et al. 2007). 
The conserved oligomeric Golgi complex is an eight subunit protein 
consisting of two lobes: COG 1 -4 form lobe A and COG 5-8 form lobe B (Ungar, 
Oka et al. 2002; Loh and Hong 2004). The COG complex is vital for normal 
Golgi morphology and structure. It is believed that COG complexes are involved 
in membrane trafficking and/or compartment function (Ungar, Oka et al. 2002). 
Defects in COG function can cause abnormalities in intracellular protein sorting, 
protein secretion, cell growth and glycoconjugate synthesis (Oka, Vasile et al. 
2005). Investigations of COG began in 1981 with the identification of low-density 
lipoprotein receptor (LDLR) deficient CHO cells mutants (Krieger, Brown et al. 
1981). In this study, the mutant CHO cells showed changes in LDLR 
electrophoretic mobility that was attributed to the absence of glycans. The 
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mutation in the LDLR-deficient CHO cells were later found to be defects that 
occurred in subunit 1 and 2 in lobe A of the COG complex and resulted in 
alterations of cell surface glycoconjugates (Kingsley, Kozarsky et al. 1986; Reddy 
and Krieger 1989). These CHO cells (IdlB and IdlQ lack galactose and sialic 
acid residues on the /V-glycan terminus and show heterogeneity in sialic acid 
content on O-glycans. Addit ional ly, the mutant cells also displayed dilated 
Golgi cisternae. Abnormal glycosylation attributed to Golgi function have also 
been reported in yeast mutants with COG defects (Whyte and Munro 2001; 
Conde, Pablo et al. 2003; Corbacho, Olivero et al. 2004). Deletions of any 
subunit in lobe A has severe effects in yeast growth, whereas deletions in 
subunits within lobe B have only mild consequences (Whyte and Munro 2001; 
Ram, Li et al. 2002). Despite growing understanding of the COG complex, the 
overall implications involved in glycosylation remain unknown. That is to say that 
structural analysis of glycoconjugates of COG deficient cells has yet to be 
explored. 
Mutations of the COG complex subunit 7 and 8 cause a congenital 
disorder of glycosylation type lie and llh in humans (Wu, Steet et al. 2004; 
Spaapen, Bakker et al. 2005). Additionally, mutations in subunit 1 also cause a 
CDG type ll/COGC-1 illnesses (Foulquier, Vasile et al. 2006). The first patient 
diagnosed to date with CDG-ll/COGC-1 suffers from hypotonia, ventricular 
hypertrophy, growth retardation, progressive microcephaly and failure to thrive. 
Mutations in the COG subunits impair the integrity of the whole complex and lead 
to disruption of Golgi trafficking and glycosylation. Since all COG-based CDG 
disorders ultimately alter Golgi function through a single complex, it would be 
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expected that the disease would manifest consistently form case to case. In fact 
similarly to CDG-I, clinical presentation is very heterogeneous. The COG 
complex has been studied considerably at the cellular level, but its role in animal 
development remains unknown. As such, it is important to understand the global 
impact that the COG complex has on N- and O-glycans throughout the body. 
Recently, a C. elegans strain containing a mutation in the first subunit of 
the COG complex was created using a Tc1 transposon (Kubota, Sano et al. 
2006). In C. elegans, the COG complex acts in the glycosylation of MIG-17, a 
member of the ADAM family of proteases that is required for gonadogenesis. 
Worms lacking the cogcA gene show altered gonad morphology due to 
misdirection of the distal tip. RNAi knockdown of all 8 subunits of the COG 
complex in C. elegans also trigger gonadal migration defects suggesting a 
common pathway that regulates gonad development (Kubota and Nishiwaki 
2006). Nishiwaki et al. prepared a model for the role of the COG complex-
dependent glycosylation of MIG-17 ADAM protease. In brief, the COG complex 
is required for sorting/stabilizing the MIG-23/Golgi NDPase along the body wall 
muscles. As a result, MIG-23/Golgi NDPase hydrolyzes/ UDPs to UMPs. UMP 
export from the Golgi is vital for the higher energy UDP-sugar to be transported 
into the Golgi. The UDP-sugar is required for MIG-17 glycosylation. Therefore 
the COG complex is indirectly required for glycosylation of MIG-17 (Kubota and 
Nishiwaki 2006). It was also observed that the cogc-1(k179::Tc1) mutants exhibit 
more robust phenotypes than mig-17(k113) mutants suggesting that 
glycoproteins other than MIG-17 are affected by the COG complex. 
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All eight mammalian COG components are conserved in C. elegans 
(Kubota and Nishiwaki 2006). The C. elegans COGC-1 deficient strain presents 
an opportunity to study COG function in glycosylation. Currently, C. elegans is 
the only viable model organism lacking COG expression. Although defects in 
COG-1, COG-7 and COG-8 were found to affect the trafficking of glycosylation 
machinery, the molecular mechanisms linking glycosylation defects to clinical 
presentations remain to be elucidated. 
6.1 Materials and Methods 
N2 (Bristol) and NF299 cogc-1 (k179) strains used were obtained from the 
Caenorhabditis Genetic Center at the University of Minnesota. Mixed stage N2 
and NF299 C. elegans strains were separately grown on large trays (6 trays per 
strain) containing peptone rich nematode growth media (NGM) and a bacterial 
food source of the E. coll OP50 strain as described (Hope 1999). Prior to the 
clearing of the bacterial lawns, 3 aliquots of 250 ml_ cold distilled de-ionized 
(DDI) water was used to rinse animals from the tray. The worm solutions were 
centrifuged at 800 RCF (relative centrifugal force) for 4 minutes at 4°C. The 
supernatant was removed and the worms were washed with cold (DDI) water, 
spun at 1000 RCF for 60 seconds at 4°C until the supernatant was clear. The 
worm pellet was re-suspended in 20 ml_ cold DDI water. To this solution, 30 ml 
of cold 50% sucrose solution was added and mixed by inversion. Each tube was 
centrifuged at 50 g for 5 minutes at 4°C. The top layer of the solution, containing 
live animals, were aspirated and collected in a fresh tube containing 20 ml_ cold 
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DDI water. Tubes containing live sample were centrifuged at 1000 g for 2 
minutes at 4°C. This step was repeated once with DDI water and once with M9 
solution (Ausubel 1999) to remove excess sucrose. The worm solution was 
centrifuged again at 1000 g for 2 minutes at 4°C and the supernatant was 
removed. The pellet was re-suspended in 5 volumes of M9, agitated at room 
temperature to allow the gut contents to be digested. A final series of three DDI 
water washes was performed to remove the gut contents. 
Roughly, 1g of wet weight worms (~1.5 ml_), thawed from a frozen pellet, 
was added to 1.5 ml_ CHAPS lysis buffer containing 4% CHAPS, 8M urea, 40 
mM Tris-HCL pH=8, 65 mM dithiothreitol (DTT). Worms were lysed using a 
Pressure Biosciences Barocycler NEP2320 (South Easton, MA) with 20 cycles, 
each consisting of 40 seconds at 35,000 PSI, followed by 10 seconds at ambient 
pressure. Whole lysate protein concentration was quantified via Bradford assay 
(Pierce, Rockford, IL) using a UV-Viz spectrophotometer (Shimadzu Corporation, 
Kyoto, Japan). Sufficient lysate to yield 5 mg protein was transferred to a glass 
culture tube (13 x 100mm) and protein was precipitated using 15% trichloroacetic 
acid (TCA) for one hour on ice. Following precipitation, the sample was 
centrifuged at low speed for 15 minutes. After the supernatant was discarded, 
the protein pellet was washed and vortexed with 2 x 1 ml_ cold acetone, and 2 x 1 
ml chloroform : methanol : water (10:10:1), with centrifugation between each 
wash. The protein pellet was dried under N2 flow and lyophilized overnight. 
Prior to A/-glycan release, the protein pellet was vacuum-dried over P205 
for 48 hours. 500 u.L of anhydrous hydrazine (Sigma-Aldrich, St. Louis, MO) was 
added to the dried protein pellet and heated at 100°C for 6 hours. Samples were 
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cooled to room temperature at which time the hydrazine was removed under N2 
flow. Samples were then lyophilized overnight. The released glycans were re-A/-
acetylated using 150 u.L acetic anhydride in 300 pL of saturated sodium 
bicarbonate on ice for 30 minutes, followed by 1 hour at room temperature. The 
samples were desalted on a DOWEX 50 W X8-400 cation-exchange resin 
(Sigma-Aldrich, St. Louis, MO). Free A/-glycans were purified using a hand-
packed column containing 500 u.L of medium fibrous cellulose. The column was 
washed with 4:1:1 n-butanol: ethanol: water to remove the peptide components. 
A/-glycans were eluted with 1:1 ethanol: water. AMinked glycans were reduced 
with a 200 pL solution of 10 mg/mL sodium borohydride (NaBH4) in 0.01 M 
NaOH for 1 hour on ice followed by room temperature overnight. To stop the 
reduction reaction, glacial acetic acid was added drop-wise until the sample pH = 
5. Borate was removed by coevaporation of 3 ml_ ethanol, 2 X 2mL of 1% acetic 
acid in methanol, and 2 X 2 ml_ toluene. The reduced A/-glycans were dissolved 
in water and desalted on a pre-conditioned 1.5 ml_ column of porous graphitized 
carbon (Alltech Associates, Deerfield, IL). After washing the column with 3 ml_ of 
water, A/-glycans were eluted using 3 mL of 25% acetonitrile/water. Purified N-
glycans in solution were dried in a SpeedVac® Concentrator (Savant 
Instruments, Holbrook, NY). 
After reduction, A/-glycans were permethylated as described (Kerek 1984). 
Briefly, dried glycans were dissolved in 500 uL of dimethyl sulfoxide (DMSO) 
(HPLC grade, Sigma-Aldrich, St. Louis, MO), followed by addition of powdered 
sodium hydroxide (99.999%, Sigma-Aldrich, St. Louis, MO). After vortexing, 100 
mL of iodo-methane (99.9%, Sigma-Aldrich, St. Louis. MO) was added. Sample 
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tubes were flushed with argon, capped and wrapped in aluminum floil and 
vortexed for 1 hour. Samples were placed on ice and 1 ml_ of water was added 
to each sample to stop the reactions followed by 1 mL of HPLC grade 
dichloromethane. The sample mixtures were vortexed and the bottom organic 
phase (containing A/-glycan) was removed and put into a clean test tube. The 
dichloromethane addition was repeated twice and each extract was pooled. The 
new tube containing the organic phase was washed 5 times with HPLC grade 
water, removing the water layer after each wash. The dichloromethane was 
evaporated under N2flow, lyophilized overnight and stored at -20°C. 
Both non-reduced and reduced A/-glycans spectra were generated using a 
MALDI-CFR mass spectrometer (Kratos-Shimadzu Analytical, Manchester, UK) 
equipped with an ultraviolet 337 nm wavelength nitrogen laser. In the case of 
non-reduced samples, 100 pL of HPLC grade water was added and vortexed. 
One pL of reconstituted sample solution was mixed with 1 pL of 2,5-dihydroxyl 
benzoic acid matrix (12 mg/mL in 50% (v/v) acetonitrile aqueous solution) on a 
stainless steel MALDI target plate. For methylated samples, 75 pL of methanol 
and 25 pL was used in place of water alone. All samples were ionized with 50-
60% of the maximum power while rastering on the plate surface. Mass spectra 
were acquired by averaging -200 profiles generated by 5 laser shots per profile 
with the post extraction parameter optimized at m/z 2500. Spectra processing 
was performed with Kratos Launchpad software. 
Spectral peak annotation was performed initially by using the online 
program Glycomod Tool, a package under the ExPASY (Export Protein Analysis 
System) proteomics server of the Swiss Institute of Bioinformatics (Gasteiger, 
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Gattiker et al. 2003). GlycoMod can predict the possible oligosaccharide 
compositions from their experimentally determined masses and on compositional 
constraints applied by the user (i.e. mass tolerance). 
MSn A/-glycan mass spectra were obtained with a linear ion trap LTQ 
mass spectrometer (ThermoFinnigan, San Jose, CA) equipped with a TriVersa 
Nanomate® automated nanoelectrospray ion source supported with automation 
and related computational tools. Dried samples were diluted in 150 u.L methanol 
and 50 u.L water. Samples were infused (10 uL) at a low flow rate of 0.30 uL/min 
and the spectra were collected using Xcaliber 2.0 software (ThermoFinnigan, 
San Jose, CA). Signal averaging was accomplished by adjusting the number of 
microscans within each scan, generally ranging between 3-5. Collision 
parameters were left at default values with normalized collision energy set to 
35%. Activaiton Q was set at 0.25, and activation time for 30 ms. All ions were 
sodium adducts. 
6.2 Results and Discussion 
The consequence of aberrant glycan structures, specifically in CDG 
patients, is not known. The human glycome is equally indefinite which 
complicates our understanding of carbohydrates in human development and 
disease. Current glycobiology efforts need to be two fold. Firstly, like the human 
genome sequencing initiative, the human proteome and glycome need to be 
precedent. This is an infinitely more complex challenge than the genome due to 
the nature of posttranslational modifications, which is both time and tissue 
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dependent. The second effort is more fundamental and perhaps an easier task, 
which should aim to understand the cellular biosynthesis and structure of 
glycoconjugates. Comparatively glycan microheterogenieity observed in 
metazoan cells is loosely defined by a small set of glycosylation enzymes. The 
complexity of glycan structure (topology, linkage, anomericity and monomer 
identification) is in most cases, assumed. Assuming carbohydrate structure 
could have dramatic effects in the future of functional glycomics as well in clinical 
treatment for glycosylation deficient diseases. To tackle the former goal, 
glycobiologist need to define a strategy for comprehensive carbohydrate 
structural analysis and establish it as fact. In this study, an established mass 
spectrometry-based method (Reinhold, Reinhold et al. 1996; Sheeley and 
Reinhold 1998; Ashline, Singh et al. 2005; Hanneman, Rosa et al. 2006) is 
utilized to understand the global glycomic consequence of a CDG-ll/COGC-1 
condition modeled in C. elegans. 
Understanding the processes involved in the A/-glycosylation pathway is 
essential to understand the biochemical basis of known CDG as well as of types 
still to be discovered. In discovering the functions of glycan structures as 
modulators of glycoprotein activity, comparative analyses of mutated genes that 
target glycosylation enzymes have been the most useful. Null mutations of 
glycosyltransferases, glycosidases and sugar-nucleotide transporters have 
provided extensive information contributing to structural diversity, but the early 
conjecture of one gene, one enzyme is exceedingly unlikely. That questons how 
so many glycoforms exist when the biology seems to be so limited. Most likely, 
the answer lies in the complexity of the Golgi. 
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To resolve this problem, a comparative analysis was performed with a C. 
elegans mutant that not only modeled a CDG-ll/COGC-1 illness, but also 
investigated the effects of a component of Golgi transport. A comparative 
analysis in C. elegans enables this investigation to examine the complete 
glycome and thus establish a deficient-function to structure relationship not 
possible in higher model organisms. The investigation is a two pronged 
approach: (1) identify and determine the prevalence of each glycan composition 
in each sample's glycome (N2 and NF299); and (2) characterize the structure of 
specific compositions to determine any glycosylation patterns unique or absent in 
the mutant strain. This systematic approach will establish a global glycome 
pattern that is unique to COG deficiency and will elucidate aberrantly expressed 
structures observed in CDG-II. 
6.2.1 Carbohydrate Structural Analysis through Mass Spectrometry 
The initial step towards investigating alterations in glycosylation is 
identifying the total glycome (i.e. glycan compositions) in each sample. This can 
be performed by MS profiling of native and permethylated samples on a MALDI-
TOF instrument to determine molecular compositions. MALDI-TOF-MS is a 
useful tool that requires minimal sample and is highly sensitive, accurate and 
reproducible (Harvey 1999; Wada, Azadi et al. 2007). Permethylation 
derivitization of glycans is a useful step that not only aids in purification, but also 
enhances sensitivity up to an order of magnitude and offers predictable 
fragmentation patterning in both tandem mass spectrometry (MS/MS) and 
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sequential mass spectrometry (MSn), which is described below. (Hakomori 1964; 
Reinhold, Reinhold et al. 1996; Ciucanu and Costello 2003). 
MALDI-TOF MS is used not to define structure, but as a guide to establish 
the presence of compositions or even patterns of glycan compositions. In a 
comparative analysis, the ideal goal is to discover structures that are unique to a 
particular sample. This may be observed as a complete absence of a molecular 
composition (i.e. a missing peak in one sample and its presence in the other) or 
as a structural isomer that may be as subtle as a change in topology or linkage. 
In either case, the application of both MALDI-TOF and electrospray ionization-ion 
trap (ESI-IT) mass spectrometry is a key dual technique for glycan sequencing. 
ESI-IT provides the sensitivity and specificity required for carbohydrate structural 
mining. 
Sequential mass spectrometry with an ion trap enables a robust and 
powerful method for oligosaccharide analysis not capable by tandem MS/MS 
alone. This method, using gas-phase isolation coupled with and multiple rounds 
of collision induced dissociation (CID), requires no chromatographic separation 
and is an unexcelled instrument for structural elucidation of complex 
oligosaccharides (Reinhold, Reinhold et al. 1995; Reinhold, Reinhold et al. 1996; 
Reinhold and Sheeley 1998; Sheeley and Reinhold 1998; Ashline, Singh et al. 
2005; Hanneman, Rosa et al. 2006). The strength of MSn analysis of 
permethylated glycans is its ability to track precursor masses through sequential 
CID disassembly steps. Permethylation is crucial for disassembly because it 
converts all native hydroxyl functional groups into methyl ethers (Kerek 1984; 
Ciucanu and Costello 2003). Principally, upon disassembly, the methylated 
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product ions leave "scars", or an hydroxide, at the point of cleavage that is helpful 
to assign glycosidic linkages. 
6.2.2 Native Molecular Compositional Analysis via MALDI-TOF MS 
MALDI-TOF-MS profiling of native-reduced N2 wild-type samples 
confirmed the presence of all /V-glycans previously reported released via 
hydrazinolysis (Hanneman, Rosa et al. 2006; Paschinger, Gutternigg et al. 2008). 
Firstly, glycans were released by hydrazinolysis, reduced and profiled in their 
native species (Appendix B). This step is a comprehensive carbohydrate 
analysis by chemically releasing those /V-linked core modified structures that 
prevent endoglycosidase action. C. elegans express endogenous O-methylated 
glycans whose signature is transparent by the methylation protocols used. 
However, such structures can be identified by a CD3-methylation. The biological 
function of glycan O-methylation is not completely understood, but it is known 
that O-methylated glycans act as a highly specific targets of host antibody 
recognition in the parasitic helminth Toxocara canis (Schabussova, Amer et al. 
2007). 
MALDI-TOF profiling of native /V-glycans from N2 and NF299 confirm the 
presence of /V-glycan compositions, with the predominant peaks representing 
pauci- and oligomannose structures (Figure16). This analysis was performed 
with the aid of the search tool Glycomod, which matches molecular ion masses 
(m/z) to oligosaccharide compositions. Although the various fucosylated and 











































































































































































































































Currently, there is no established standard approach for carbohydrate 
quantification, however a multi-institutional study has been completed in an effort 
to meet the demand for mass spectrometry based analysis (Wada, Azadi et al. 
2007). Likewise, in this study, comparative quantitative analysis consisted of 
determining the percent composition of each molecular composition in a single 
spectrum. In short, the percent composition for each glycoform was defined as 
the intensity of each individual molecular composition m/z values normalized to 
the intensity sum of all the glycans ions between the appropriate mass-to-charge 
range in both samples (Appendix C). This breakdown allows for individual, as 
well as /V-glycan types, to be compared as well as to identify glycosylation 
patterns distinct to N2 or NF299. For example the relative abundance of 
endogenous 0-methylation was less in the NF299 cogc-1(k179) strain (Table 7). 
Moreover, high-mannose structures are slightly more abundant in the mutant 



























































































% of the total 
glycome 28.24±0.43 14.53±0.32 
Table 7. Relative quantities of native O-methylated A/-linked glycans from 
N2 and NF299 strians. Molecular compositions along with the theoretical 
mass of the singly charged sodium adducts are shown. The first number 
under % composition represents the relative intensity to the sum of all 
measured glycan intensities and the second number is the standard deviation. 
The percent of the total glycome that represent O-methylated structures is 
also provided 
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6.2.3 Permthvlated Molecular Compositional Analysis via MALDI-TOF MS 
After native analysis, A/-glycans were permethylated and profiled (Figure 
17). Similarily to native glycan analysis, the search tool Glycomod was used to 
match molecular ion masses (m/z) to oligosaccharide compositions. The search 
parameters were strict; the experimental values were compared to hypothetical 
mass values within a ±0.3 Dalton threshold. After the presence of A/-glycans was 
confirmed, the experiment was repeated twice from worm growth to MS analysis 
maintaining all experimental constraints (Appendix B). The two replicates 
confirmed the molecular compositions of hydrazine-released A/-glycans form C. 
elegans as well as the profile trends seen in the first spectra. 
As in the native compositional analysis, the relative abundances of 
paucimannose, high mannose and fucosylated structures were calculated by 
dividing each molecular composition intensity by the intensity sum of all the 
glycans (Table 8). Phosphorylcholine-rich and truncated complex structures 
were not included in the comparative because they were not detected in 
significant amounts by previous hydrazinolysis-based reports (Hanneman, Rosa 
et al. 2006) and only represent a minority of molecular compositions in the C. 
elegans glycome respectively (Paschinger, Guttemigg et al. 2008). 
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Figure 17. MALDI-TOF profiles of permethylated /V-glycans. The spectra mass 
ranges from 1700-2750 m/z. Molecular compositions that appear to be absent in the 
NF299 strain are marked with an * and represent composistions with 4 fucose 
residues. N=HexNAc (e.g. N-acetylglucosamine, N-acetylgalactosamine), H=Hexose 























































































































































Table 8. Relative quantities of permethylated AZ-linked glycans from N2 and 
NF299 strians. Molecular compositions along with the theoretical mass of the 
single and double charged sodium adducts are provided. The first number under 
% composition represents the relative intensity to the sum of all measured glycan 
intensities and the second number is the standard deviation. Tetra-fucosylated 
compositions, which are significantly reduced in the mutant strain, are highlighted 
in grey. N=HexNAc (e.g. N-acetylglucosamine, N-acetylgalactosamine), 
H=Hexose (e.g. galactose, mannose, glucose), F=Deoxyhexose (e.g. fucose) 
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Mass spectrometric analysis of permethylated oligosaccharides showed 
an absence of tetra-fucosylated glycans as well as a substantial decrease in tri-
fucosylated glycans (Figure 18). Comparatively, the frequency of mono- and di-
fucosylated compositions did not differ significantly between strains (Figure 19). 
This qualitative change in glycan distribution (namely fucosylated structures) was 
not detected in the native-reduced mode and can possibly be due the 
permethylation step itself which also serves as a purification step. The AA-glycans 
which are present in low abundances in native profiles became more detectable 
as permethylated oligosaccharides. Additionally, all tetra-fucosylated 
compositions with 0, 1 or 2 endogenous O-methyl groups will be observed as a 
single composition (m/z) after permethylation. Permethylation will have 
converted all the remaining hydroxyl groups to methyl ethers, making 
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Figure 18. The prevalence of /V-glycans by subtype. Relative abundances of 
each glycan type are compared illustrating the decrease of tetra- and tri-fucosylated 
structures in the NF299 strain. Additionally, the occurance of high-mannose 
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Figure 19. Comparative analysis of fucosylated /V-glycans from C. elegans 
organized by subtype. The vertical axis represents the percent relative abundance of 
each composition the glycome. The horizontal axis represents the molecular 
compositions (N=N-acetylglucosamin, H=Hexose and F=Fucose). Error bars represent 
the coefficient of variation, standard deviation/mean x 100, which indicates the percent 
variance of molecular compositions peak intensities between the individual samples. 
The molecular compositional analysis of both native and permethylated 
samples revealed four major trends of /V-linked glycosylation in the NF299 strain. 
First, endogenous O-methylation, which is prevalent in wild-type C.elegans, is 
decreased in COGC-1 deficient animals. The percent of O-methylated structures 
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in the total glycome of N2 and NF299 is 28.24±0.43 and 14.53+0.32 respectively. 
Second, in native and permethylated profiles, the occurance of high-mannose 
compositions is elevated in the NF299 strain. In the native profiling mode the 
percent of the total glycan composition in NF299 is 44.98±1.07%, compared to 
35.66±1.17% in N2. After permethylation the percent of high-mannose in NF299 
is 39.61 ±1.23 and 29.96±1.32 for N2. Third, tetra-fucosylated structures are to a 
large extent absent in NF299 strains. Tetra-f ucosylated compositions consist of 
1.43±0.91% of the total permethylated NF299 glycome. Alternatively, the N2 
glycome is 9.07±0.91% composed of tetra-fucosylated compositions. Fourth, tri-
fucosylated structures are decreased in the NF299 strain. The amount of tri-
fucosylated structures is 11.39±1.13% in NL229 and 19.07±1.47 in N2. The 
glycomic patterns at this stage are merely a useful tool to determine the fine 
structures present in the comparative anlysis. Clearly, the NF299 strain indicates 
a discrepancy in fucosylation, specifically fucose-rich structures, but the exact 
nature of the defect is unclear. Structural characterization by MSn of the N-
glycans will help elucidate the specific glycosylation patterns seen in CDG-
ll/COGC-1 type conditions. 
6.2.4 Structural Characterization of A/-qlvcans via MS" 
Single MS and MS/MS analysis of carbohydrates provides the basis for 
compositional assignments. Compositions however cannot define the fine 
structure of glycans, namely linkage and topology. Within a single peak of a MS1 
profile, several isomers and isobars may exist. Isomers are defined as structures 
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with identical atomic compositions, but arranged in different stereo and structural 
configurations. A mass profile is transparent to all isomer types and to uncover 
such detail fragments must be generated, and sometimes multiple times. In the 
current study, a differential analysis of N2 Bristol and NF299 cogc-1(k179) worms 
was carried out by sequential MS for a comprehensive evaluation of structural 
detail. 
The goal of this project was to determine the function of the COG complex 
and its role in glycosylation in C. elegans. As found in the MALDI-TOF profiling, 
the degree of fucosylation in the NF299 strain appears to be below normal or 
absent compared to the wild-type. Detailed glycan sequencing will answer three 
key questions: 1) is the COG complex required for synthesis of wild-type N-
glycans; 2) does the NF299 strain assemble fucose-rich glycans (FUC4) and 3) is 
the location of fucosylation (i.e. topology) different than wild-type structures . 
Optimistically, this report will shed light on the role of the COG complex in CDG-
ll/COGC-1 conditions and in doing so will be the first comparative analysis where 
a glycosylation structural defect is found that is not directly linked or caused by a 
defect in a glycosyltransferase, glycosidase or carbohydrate-nucleotide 
transporter. 
6.2.5 Structural Characterization of GlcNAcpMans 
To discern the pattern and extent of fucosylation, first N2 strains with 
molecular compositions of zero, one, two, three and four fucose residues were 
examined via MSn disassembly to establish A/-glycan wild-type standards. 
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Additionally, only certain molecular compositions are present with these 
compositions. These glycans are GlcNAc2Man4Fuci.4, GlcNAc2Man5Fuci.4, 
GlcNAc2Man6Fuci-4 and GlcNAc2Man7Fuci-4(the penultimate and reducing end 
GlcNAc residues were components of these compositions). Since 
GlcNAc2Man5Fuci-4 structures are present in higher abundances in both strains, 
it was used for comparative analyses. Also, higher levels of abundance are 
helpful for isolation, fragmentation and analysis of molecular ions by MSn 
techniques. Additionally, structural isomers are more prevalent in Man5 than in 
Man6 compositions (Prien 2009). Limitations and low levels of detection in 
Man7Fuci-4 compositions make Man5Fuci-4 more suitable for examination. After 
the N2 wild-type structures were established, structural elucidation and MS" of 
the NF299 strain was carried out. 
The first composition to be discussed in the analysis is Man5GlcNAc2. 
Generally, the structure of GlcNAc2Man5 is 
described as having two mannose residues on 
the 6-arm of the conserved chitobiose core 
structure (1,4-GlcNAc(31,4-GlcNAc) (Figure 20). 
Until recently this was the only Man5 structure 
believed to be formed (Magnelli, Cipollo et al. 
2008). Cipollo et al. detected one additional 
isomer in the MS3 spectrum but its structural 
detail was not further analyzed. In this study the 
presence of 4 Man5 structural isomers was 
chitobiose 
core 
Figure 20. GlcNAc2Man5and 
the chitobiose core. The 
chitobiose core structure is 
present in all A/-linked 
glycans. 
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demonstrated in the wild-type N2 and NF299 strains. The MS2 spectra of 
Man5GlcNAc2 provides little structural information due to the facile neutral loss of 
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Figure 21. MS3 of m/z 1302 from GlcNAc2Man5(/n/z1595). The top two profiles are 
MS2 spectra of GlcNAc2Man5 from N2 Bristol and NF299 cogc-1 (k179) C. elegans 
strains. The bottom profiles are MS3 of the m/z 1302 ion, which is the neutral loss of 
the reducing end GlcNAc. Corresponding structures are shown below each profile 
set and all ions are sodium metal ion adducts. 
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From the MS3 profile of GlcNAc2Man5 (m/z 1595+-+ m/z 1302+) two 
structural isomers are immediately apparent (Figure 21). In addition to the 
classical Man5 structure, a second structure was indicated by the presence of the 
m/z880 ion (Figure 22). It is improbable to generate an m/z880 fragmentation 
of the Man5 structure in Figure 21, but could suggest an isomeric structure 
having a terminal non-reducing disaccharide element like that below. 
1377 445 
Figure 22. GlcNAc2Man5 Structural Isomer #2. The MS3 profile of m/z 
1302+ ion shows the presence of a structural isomer from the m/z 880 peak. 
The accurate terminal hexose linkages are not determined and are shown 
as 1,4 linked. 
The Hex-Hex loss could occur from either the 6- or 3-position of the 
central mannose within the /V-linked core and this was supported with the 
detection of the m/z 533 and m/z 547 ions in the MS4 spectra (Figure 23). The 
MS4 spectrum of m/z 880 confirms the presence of this isomer but only with 
further disassembly can one discern the linkage of the terminal Hex-Hex 
disaccharide. Both N2 and NF299 strains exhibit this structure in equal amounts 
based on abundance. The neutral loss of the Hex-Hex disaccharide appears to 
occur more readily on the 3-arm of the core, but quantification could not be 
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considered without knowledge of each ions' pathway and ionization cross 
section. 
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Figure 23. MS4 of m/z 880 ion from Man5 Isomer #2. MS4 spectra and 
fragment assignments from the /7?/z880 ion confirms the presence of an 
additional Hex-Hex disaccharide from the m/z 445 and m/z 463 ions. 
What is not evident in the MS3 spectra in both strains is the structure of the 
m/z 667 C-type ion. The topology of the m/z 667 ion is presumably a branched 
structure consisting of three mannose residues. However, when the m/z667 ion 
is fragmented from the MS4 spectra after the neutral loss of a terminal hexose 
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(m/z 1595-* 1302-* 1084—>-667), the fragment ions demonstrate the presence of 
an additional linear topological isomer (Figure 24). The m/z227, m/z519 and 
m/z 563 ions can only be created from a linear precursor structure. Although it 
does appear that the branched structure is more commonly formed in both 
strains based on the relatively more abundant m/z 301 and m/z 375 ions. 
Although further MSn disassembly would be required to define linkage for the 
linear structure, the signal strength from the NF299 strain did not permit 
additional fragmentation. However, MS6 spectra has been generated from the N2 
strain and the m/z 563 fragment suggests that the terminal and penultimate 
hexose residues are connected by a 1,2 and 1,3 linkage respectively and not 1,4 
as illustrated below. (Appendix D; Figure D1). 
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Figure 24. MS5 spectra and fragmentation assignments of m/z 667 from Man5. 
Isolation and fragmentation of the m/z 667 C-type ion (three terminal mannose 
residues) after the neutral loss of one terminal hexose (m/z 1084 precursor) reveals 
the presence of three isomers based on the presence of the m/z 563 peak that can 
only be created from a linear structure. 
A fourth Man5 structural isomer was detected from the neutral loss of three 
terminal and one branched hexose residues. This fragmentation pathway tracks 
the following ions: m/z 1595->m/z 1302^m/z 1084-»m/z 866^m/z 648. The 
MS4 spectra from the m/z 1084 parent ion contains many peaks that can be 
formed from the neutral loss of the reducing end GlcNAc and one terminal 
mannose residue from all three of the isomers above. Isolating the m/z866 peak 
from an additional neutral loss of a terminal hexose still produces fragment ions 
that can be generated from these isomers (Figure 25). So it is necessary to 
isolate the m/z 648 ion and examine the core GlcNAc and Man residues. 
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Only one of the isomers described above has three terminal hexose 
residues and can produce an m/z 648 ion in the MS5 spectra. MS6 spectra of this 
ion illustrates not only the presence of the branched crt ,3 and a1,6 core mannose 
residue (m/z 458), but additionally shows trace amounts of an crt,3, a1,6 and 
crt ,4 bisecting core mannose structure from the m/z AAA peak, which has not 
previously been reported (Figure 26). Because the chitobiose core is considered 
to be conserved amoung all N-glycan structures, any implications this elaboration 
would have on glycoprotein structure or function is speculative. It is possible that 
the bisecting mannose is not a product of the LLO pathway, but is constructed in 
the Golgi during Akjlycan processing. The extent of core modifications that are 
unique to C. elegans would suggest the latter scenario and perhaps the 
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Figure 25. MS5 of m/z 866 from GlcNAc2Man5 (m/z 1595). The top two profiles 
are MS4 of GlcNAc2Man5 after the neutral loss of the reducing GlcNAc and one 
terminal Hex residue (m/z 1084). The corresponding structure with fragments is 
shown. Isolation of the m/z 866 ion which is an additional neutral loss of a terminal 
Hex generates the bottom MS5 profiles. Additionally, each profile set and all ions 
are sodium metal ion adducts. 
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Figure 26. MS6 of /n/z 648 from GlcNAc2Man5 (m/z 1595). The top spectra 
represent MS6 pathwayss Man5 GlcNAc2dissasembly following the neutral loss of the 
reducing GlcNAc and three terminal Hex residues. Two isomers are apparent at this 
stage and constitute the normal branched chitobiose core mannose as well as a 
bisecting chitobiose core mannose. Each profile set and all ions are sodium metal 
ion adducts. 
Figure 27. Structural Isomers of GlcNAc2Man5 in N2 
and NF299 
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6.2.6 Structural Characterization of GlcNAc?MansFuc 
The second composition analyzed was GlcNAc2Man5Fuc which has a 
single sodium adduct mass of 1769.9. However when using the electrospray ion 
trap instrument, this molecular ion appears primarily as a double sodium adduct 
(m/z8962+). The comparative analysis of the two strains aims to determine the 
aberration of fucosylation in the COGC mutant. The location of the fucose in the 
N2 wild-type is known to vary throughout the structures, from position on the 
chitobiose core to mannose residues on the outer arm (Hanneman, Rosa et al. 
2006). With only a single fucose in the composition, the possibility for structural 
variation between the strains is limited. The relative abundance of mono-
fucosylated structures remains mostly equal, with the N2 and NF299 glycome 
having 18.9 ± 1.8% and 21.2 ± 1.3% respectively. 
MS2 profiles of GlcNAc2Man5Fuc provide some topological information 
with regard to fucose location. As stated previously, a common fragmentation 
pattern observed in the MS2 profiles is a result of labile glycosidic bond cleavage 
between the chitobiose residues. This generates primary B- and Y-
complementary ions that can help locate a single fucose (i.e. on the reducing end 
GlcNAc or on a terminal hexose). Cross ring cleavage fragment ions (A- type) 
that are instrumental to distinguish isomers and linkage positions are exposed 
only with smaller sized oligomers where the number of oscillators are limiting to 
dissipate the collision energy. 
The MS/MS profiles of N2 and NF299 strains differ slightly (Figure 28). 
The B/Y ion complementation suggests three locations where fucose is added. 
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The three positions are based on the following ion fragment pairs: m/z 316/1476, 
m/z490/1302 and m/z694/1098. However, the NF299 strain only contains trace 
amounts of the m/z 316 and m/z 1476 ions, suggesting that outer arm 
fucosylation is decreased in the mutant. From the N2 data set it can be inferred 
that, under normal conditions, fucose is either added on; 1) a terminal hexose or 
less likely the penultimate GlcNAc, 2) the reducing end GlcNAc with no other 
modifications or 3) the reducing end GlcNAc with an additional hexose residue. 
The MS2 spectra provide no additional structural information. It is crucial to note 
that in the figure below the cartoon structures do not represent the exact location 
of fucose or the accurate overall topology. In fact in N2 wild type C. elegans, the 
GlcNAc2Man5Fuc composition includes 7 different topologies. 
100 694.4 
400 600 800 1000 1200 1400 1600 1800 
m/z 
C. e/egans_N2 MS28962* 







I | 853.5 







400 600 800 1000 1200 1400 1600 1800 
m/z 
C. e/egans_cogc-1 MS2 8962* 
45 scans NL: 3.00E1 
Figure 28. MS2 of GlcNAc2Man5Fuc (m/z 8962+). B/Y ion complementation from 
MS/MS profiles of m/z 8962+ reveals the relative location of fucose. The cartoon 
structures represent compositions only. Open circle, glactose; filled circle, mannose; 
filled triangle, fucose; filled square, /V-acetylglucosamine. 
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The first compositions to be evaluated comprise the m/z 694 and m/z 
1098 B/Y ion complements. The most predominant peak in the MS3 spectra of 
the m/z 1098 ion is m/z 880, which is the neutral loss of a terminal hexose 
(Figure 29). Surprisingly, unlike the GlcNAc2Man5 isomer that generated a 
similar m/z 880 peak corresponding to a branched structure (Figure 23), these 
spectra lack the indicative m/z 445 peak characteristic to a linear hex-hex 
disaccharide unit. The m/z 445 ion is usually the most common ion peak 
generated from a precursor that does exhibit such a structure. However, there 
are two peaks that can only be created from a linear branched structure. These 
are m/z 676, which is the Y-ion complement of the sodiated B-ion m/z 445 
disaccharide loss, and m/z 431, which is formed from the neutral loss of a hex-
hex disaccharide and a terminal hexose. Additionally there are two peaks that 
correspond to an ion created from a cross ring cleavage that contains a linear 
hex-hex unit. These two peaks are the m/z 635 and the m/z 533 peak. These 
ions can be generated from a different structural isomer, but from the spectra do 
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Figure 29. MS4 of m/z 880 from GlcNAc2Man5Fuc (m/z 8962+). The top two 
profiles are MS3 after the loss of the GlcNAc/Fuc/Gal reducing end structure 
indicated at the top left on the spectra. The bottom profiles are MS4 of the m/z 
880 ion, which is the neutral loss of a terminal hexose. 
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Next, the m/z 880 ion in the MS3 spectra from the neutral loss of an non-
defined terminal hexose was isolated and fragmented. The MS4 spectra created 
reveals inconsistencies with the proposed branched structure above. In addition 
to a branched isomer, a bisecting structure is also evident, similar to the bisecting 
GlcNAc2Man5 structure described in the previous chapter. For example, the m/z 
327 or m/z 343 peak cannot be created from a branched structure. The most 
abundant peak in the MS2 spectra is the m/z 662 ion that is caused by the neutral 
loss of a terminal hexose. The MS5 spectra created difinitively confirms the 
bisecting mannose structure from the m/zAAA peak (Figure 30). The hydroxyl 
group at the 4-position on this mannose is evident not only from the m/z AAA, but 
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Figure 30. MS5 of m/z 662 from GlcNAc2Man5Fuc {m/z 8962+). After the neutral 
loss of the reducing GlcNAc/Fuc/Gal and two terminal Hex residues two structural 
isomers are confirmed in both strains. The m/z 458 and m/z AAA ions correspond to 
a branched and bisecting chitobiose core mannose. 
The corresponding Y-ion of m/z 1098 is m/z 694 and corresponds to a 
reducing end GlcNAc with a fucose and hexose addition. Previous reports 
identified the hexose as a terminal galactose attached in a (31,4 linkage to an 
internal fucose (Hanneman, Rosa et al. 2006). In this report, a sample of 
released glycan was treated with and without (31,4-galactosidase. The MS 
profiles from treated sample lacked complexity at the core, namely terminal 
hexose residues that were present in the untreated sample. It was concluded 
that the galactose residue was attached in p1,4 linkage to both a Fuccd ,6-
GlcNAc or FuccM ,3-GlcNAc reducing end structure. Both N2 and NF299 strains 
synthesize the (31,4Gal-Fuca1,6-GlcNAc structure and do not contain any 
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structural variations (Figure 31). Comparatively, the analysis of the m/z 694 and 
m/z 1098 B/Y complements are identical between the wild-type and mutant 
strains. 
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Figure 31. MS3 of m/z 694 from GlcNAc2Hex5Fuc (m/z 896^). 
The second B-ion to be analyzed from the GlcNAc2Hex5Fuc is the m/z 
1302 which is composed of hexose residues, presumably all mannose. Based 
on published reports on the C. elegans glycome, the two types of hexose 
residues that are present on A/-glycans are either galactose linked to a fucose 
which is bound to the penultimate or reducing end A/-acetylglucosamine or 
mannose residues added to the chitobiose core in several conformations. The 
structural variation of the m/z 1302 structure contains five mannose residues and 
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the structural detail closely resembles the isomeric structures of GlcNAc2Man5 
(Figure 32). MS2 spectra of N2 and NF299 show the most prevalent peak to be 
m/z 880 which corresponded to a branched structure. MS3 of m/z 880 from both 
strains do not exhibit any change in the distribution or intensitiy of peaks 
generated (Figure D2). Represented in trace amounts in the MS2 spectra is the 
C-type m/z 667 ion peak that contained isomers #1 and #3 described in the 
previous chapter as having either a branched or linear tri-mannose structure 
(Figure 33). The N2 and NF299 spectra of the m/z 667 from the m/z 1302 
precursor are relatively identical with the exception of the m/z463 peak 
cooresponding to a C-type hex-hex ion in the the N2 spectrum. Moreover, the 
m/z 445 which is the the B-type hex-hex ion is more detectable in the N2 profile. 
This may suggest that the linear structure is less abundant in the NF299 strain. 
However, the indicative m/z 563 ion of a linear structure is present in relatively 
equal amounts between the two. It is importatnt to note that the signal strength 
of the m/z 667 ion in the MS2 of m/z 1302 in the NF299 strain is exceeding weak 
and required over 400 scans to generate a single acceptable spectrum. This 
may contribute to the absence or undetectable ions in the NF299 profiles. Most 
importantly is that the MSn comparison of the two strains does not reveal different 
structural isomers. This includes the m/z 490 Y-fragment ions, which are the 
fucosylated reducing end GlcNAc structures (Figure D3). The abundance of 
strucutres may vary, but may or may not depend on the COG complex. 
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Figure 32. MS5 of m/z 866 from GlcNAc2Man5Fuc (m/z 8962+). These profiles 
follow the loss of the fucosylated reducing end and two terminal hexose losses. 
The MS5 profile of m/z 866 shows the presence of branched and bisecting 
isomers from the m/z 458, 444 and 417 ions, similar to the structural isomers of 
GlcNAc2Man5. Fragmentation patterns are shown on the m/z 866 precursor 
structure. 
112 
0 0 C. elegans_H2 
MS"8962* 
1 3 0 2 - 4 R 
- • • 6 6 7 
101 scans 








































































MeO—f. T ^ O H 
MeO- 259',/ 
A 
. . . ; 399 
\bMe":635 
\ 3 7 5 
/ . .ko.;. .3qi; •'; 
[375 ; MeO^,:'--'V-^~o'i i 







- | 227 
MeO—(•-.. •)—OH ; 
•yyf:/ OMe"'"-., 
259\ / \OMe 
MeO OMe 
\431 
M e O ^ 2 4 1 ; 
MeO—( ) : 






Figure 33. MS5 spectra and fragmentation assignments of m/z 667 from 
Man5Fuc. Isolation and fragmentation of the m/z 667 C-type ion (three terminal 
mannose residues) reveals the presence of three isomers. When compared to 
m/z 667 spectra of Man5, the m/z 563 peak is elevated and suggests an increase 
in linear structures compared to a branched array. 
The third B/Y ion complement from GlcNAc2Man5Fuc is m/z 1476 and m/z 
316. The m/z 1476 contains an outer arm fucose, the only such fragment ion in 
the GlcNAc2Man5Fuc MS/MS spectra. The NF299 MS2 spectrum has a 
significant decrease in the peak intensities of this ion which suggests a decrease 
in outer arm fucosylation. Unfortunatly, the signal strength of the m/z 1476 peak 
in the MS2 profile of GlcNAc2Man5Fuc in NF299 is too weak to analyze further. 
MS3 spectra from both strains were obtained, but further fragmentation steps is 
not possible due to the poor signal (Figure 34). Comparatively, the two MS3 
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profiles do provide structural information and show a disparity of isomers 
between samples. 
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Figure 34. MS3 spectra and fragmentation assignments of m/z 1476 from 
GlcNAc2Man5Fuc. Isolation and fragmentation of the m/z 1476 B-type ion reveals 
the presence of three isomers. The NF299 strain predominantly expresssed the 
isomer on the right, which does not have terminal fucosylation on a either arm. 
Terminal f ucosylated isomers are more common in the N2 strain. 
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The decrease of the m/z 1476 peak in NF299 suggests that 
GlcNAc2Man5Fuc compositions are deficient with A/-glycans having terminal 
fucose residues. /V-glycans in NF299 with a GlcNAc2Man5Fuc composition 
position the fucose on the reducing end GlcNAc exclusively with trace amount of 
terminal-fucosylated structures. The wild-type N2 strain has a considerably more 
terminal-fucosylated A/-glycans from the increased peak intensity of m/z 1476. 
Based on the MS/MS profiles of GlcNAc2Man5Fuc, the NF299 strains mainly 
contains fucose on the reducing end GlcNAc. In the N2 strain the location of 
fucose appears to be on the terminal ends and not attached to the 3-position on 
the penultimate GlcNAc, which is a common glycoform in C. elegans. This is 
based on the lack of GlcNAc-Fuc neutral loss or its presence as a sodium adduct 
(m/z 646) in the spectrum. The m/z 1231 peak corresponds to a neutral loss of 
an internal GlcNAc and the m/z 1288 peak is formed from the neutral loss of a 
terminal fucose. 
One preliminary conclusion that can be made from the decrease in the 
m/z peak in the NF299 strain is that the COG complex is required for outer arm 
fucosylation in C. elegans and that the NF299 strain does not lack nor create 
structural isomers from the N2 strain. MS" analysis at this stage does not find 
isomeric structures or peaks indicating different structures. What is evident from 
the MS/MS spectra is the change in fucosylation in the NF299 strain. The N2 
strain has at least 7 structural isomers within the GlcNAc2Man5Fuc compositon 
all of which are present in the NF299 strains. Additionally, the NF299 strain 
expresses a structure that is found in the N2 strain in trace amounts (Figure 35). 
115 
Figure 35. Structural Isomers of GlcNAc2Man5Fuc. 
The extent of outer arm fucosylation was quantified by measuring the 
relative intenisties of fucosylated outer-arm modifications in the MS2 spectra. In 
other words, the individual intensity of the non-fucosylated B-fragment ions (m/z 
1098 and m/z 1302), and single fucosylated B-ion composition (m/z 1476) was 
normalized to the sum of B-ion peaks in the spectra and calculated as a 
percentage (Table 9). Three individual trial experiments and MS2 spectra were 
generated and used to ensure a robust analysis. The table below demonstrates 
that the NF299 strain has a decrease in terminal fucosylated structures. On 
average only 2.4 ± 1.2% of GlcNAcaMansFuc compositons in NF299 have outer-
arm fucose residues, where in the N2 strain this structure is present 24.3 ± 7.6% 
of the time. The non-fucosylated terminal m/z 1302 B-ion are similar between 
strains with NF299 having 15.3 ± 4.8% and N2 having 14.1 ± 5.4% compositions. 
The relative intensities of non-fucosylated terminal m/z 1098 B-ions are dissimilar 


















24.3 ± 7.6% 
NF299 {k179) 
82.3 ± 6.0% 
15.3 ±4.8% 
2.4 ± 1.2% 
Table 9. Relative intensity of MS/MS B-fragments from GlcNAc2Man5Fuc. 
These charts show the deviation of outer-arm fucosylation the NF299 strian 
compared to wild-type N2. The percent relative intensity each composition was 
calculated based on the measured intensity of both fucosylated and non-fucosylated 
outer arm B-ions from three individual experiments. 
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6.2.7 Structural Characterization of GlcNAcpMansFuc? 
Of all the GlcNAc2Man5(Fuci-4) compositions analyzed, GlcNAc2MansFuc2 
contains the most isomeric diversity. The relative abundance of di-fucosylated 
structures in the C. elegans glycome in the N2 strain is 21.5 ±1.0%. Similarily 
the A/-glycome of the NF299 strain is 24.9 ± 0.9% di-fucosylated compositions. 
The MS/MS spectra of the doubly charged Man5Fuc2 composition (m/z 9832+) 
illustrates the presence of six B/Y complement ion fragments in both strains 
(Figure 36). These compositions range from GlcNAcMan4 and GlcNAcMan2Fuc2 
B/Y complements (m/z 894 and m/z 1072) to a GlcNAc2Man5Fuc2 B-ion with 
single reducing end GlcNAc Y-ion (m/z316 and m/z 1650). Despite the 
presence of these ions in the MS/MS profiles, the abundance of these ion differ 
between the two strains, named the abundance of the m/z 1650 and 1476 in the 
NF299 strain. The trend of decreased outer arm fucosylated observed in 
GlcNAc2Man5Fuc continues in GlcNAc2Man5Fuc2 compositions as well. This is 
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Figure 36. MS2 of GlcNAc2Man5Fuc2(m/z 9832+). B/Y ion complementation from 
MS/MS profiles of m/z 9832+ reveals the increase complexity and increased 
fucosylation on the A/-linked core. The cartoon structures represent compositions 
only and not the exact location of residues. Open circle, galactose; filled circle, 
mannose; filled triangle, fucose; filled square, A/-acetylglucosamine. 
From the absence of convincing isomeric structures in the two previously 
analyzed compositions, the investigation will focus on the location and changes 
in fucosylation between the two strains. Additionally, the comparative analysis is 
limited by the signal strength of the weakest sample and as such it is improbable 
that detailed MSn analysis is likely to establish linkage or detect the presence or 
absence of structural isomers only detectable in MSn>3 spectra. The limitations 
of sample signal is due to the presence of 6 topologies spread out in the 
GlcNAc2Man5Fuc2 composition. Despite the relatively strong abundance of this 
composition in the MS1 profiles of NF299 (Figure 17), the wide distribution of 
fragments in the MS/MS profile limit the rounds of ion isolation and 
fragmentation. To establish a structure-function relationship of the COGC-1 
complex in C. elegans, extensive MSn is not neccesary at this point. Preliminary 
data shows that the COG protein complex is required for outer-arm fucosylation 
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in GlcNAc2Mari5Fuc compositions. Additionally, the presence of tri- and tetra-
fucosylated structures are significantly decreased in this strain (Figures 18 and 
19). In order to comfirm this relationship, the tendencies of fucosylation via MS3 
in NF299 will be explored, unless further fragmentation is possible. 
Of the six B/Y ion complement fragments generated in the MS/MS profile 
from N2, all but one (m/z 1650) is present in sufficient amounts to generate a 
MS3 spectrum in the NF299 strain. Three B-ions (m/z 894, m/z 1098 and m/z 
1302) do not contain fucose residues and are the most abundant complementary 
peaks in NF299. Two fucosylated B-ions (m/z 1272 and m/z 1476) are present 
in moderate amounts in both strains. The MS3 spectra from the corresponding 
reducing end Y-ions do not exhibit isomeric structures between the strains 
(Figure D4 and D5). 
MS3 spectra of non-fucosylated B-ions are alike and suggest that the N-
linked glycan structures are similar between N2 and NF299. The MSn profiles 
and corresponding structures of m/z 894, m/z 1098 and m/z 1302 ions are 
comparable to similar ions analyzed in detail in the previous two chapters. The 
MS3 profiles of m/z 894 from GlcNAc2Man5Fuc2 do not show any significant 
variations (Figure 37). 
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Figure 37. MS3 of m/z894 from GlcNAc2Man5Fuc2. N2 and NF299 strains do not 
show any clear structural differences. 
Similarity, the MSn profiles of m/z 1098 (Figure 38) and m/z 1302 (Figure 
39) from GlcNAc2Man5Fuc2 remain the same between the strains. The MS3 
spectra from the corresponding reducing end Y-ions do not exhibit isomeric 
structures between the strains (Figure D6 and D7). However the fragmentation 
of m/z ->1302 from 9832+ differs slightly from the fragmentation of m/z 1302 from 
GlcNAc2Man5. The GlcNAc2Man5 composition contained an abundant 667 peak, 
indicative of either a branched or linear trisaccharide, but this peak is 
undetectable in GlcNAc2Man5Fuc2 compositions. The spectra of m/z 1302 
suggest the presence of two structural isomers. One isomer contains two 
disaccharide hexose residues linked to the core hexose at the 6- and 3- position. 
The second isomer has three individual hexose residues linked to the core 
hexose at the 2-, 4- and 6- position with an additional hexose linked to one of 
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those residues. Again the spectra between the two strains do not differ and 
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Figure 38. MS" of m/z 1098 from GlcNAc2Man5Fuc2. N2 and NF299 strains do 
not show any clear structural differences based on the profiles. The structural 
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Figure 39. MS" of m/z 1302 from GlcNAc2Man5Fuc2. N2 and NF299 strains do 
not show any clear structural differences based on the profiles. 
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The MS3 spectra of the m/z 1272 B-ion (Man4FucGlcNAc) differ 
considerably between strains (Figure 40). The MS3 spectra from the 
corresponding reducing end Y-ions do not exhibit isomeric structures between 
the strains (Figure D8). The most noticeble difference is the m/z 667 peak in the 
NF299 spectrum with is consistant with a tri-mannosyl C-type ion which was 
characterized in detail in the Man5GlcNAc2 chapter. In that composition the 
topology was linear and branched. The fragment ions in this profile are not 
sufficient to make definative structural assignments, however there are some 
diagnostic ions to suggest the presence of only the branched type m/z 667 
composition. These diagnostic ions are m/z 709, m/z 621, m/z 593, m/z 449 and 
m/z 431. These peaks, which correlate to two putative strucutures in Figure 39, 
are more prevalent in the NF299 and some are not detectable in the N2 strain. 
Of the structures unique to NF299, the location of fucose remains close to the 
core and not on the outer arms. The location of fucose in NF299 is linked to the 
penultimate GlcNAc with an additional hexose (presumably a galactose) or 
linked to the core branched mannose. The latter structure is novel and most 
likely less plausible, but the m/z 621 and m/z 709 peaks can only be derived 
from this structure. It is possible that these ions are resulting unique 
fragmentation of the established core fucosylated strucuture. Unfortunately 
further MSn is not achievable. The m/z 667 peak is considerably decreased in 
the N2 strains and the most widespread structure in N2 is a bi-antennary 
structure. 
An additional diagnostic peaks in the NF299 spectrum is the decreased 
m/z 1027 and m/z 1045, which are the B-type and C-type ions from the neutral 
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loss of an internal GlcNAc. This suggests that the GlcNAc residue in NF299 is 
more commonly modified with a fuc-gal disaccharide. Also the m/z 1084 peak 
generated form the neutral loss of a terminal fucose is significantly reduced in 
the NF299 strain further suggesting the prevalance of the complex core structure 
and decrease of outer arm fucose additions. 
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Figure 40. MS3 of m/z 1272 from GlcNAc2Man5Fuc2. The spectra of N2 and 
NF299 strains differ notably. The NF299 strain generates a greater amount of the 
structures shown at the top right and bottom, whereas N2 predominatly expresses 
the structure at the top left. 
The spectra of the m/z 1476 B-ion have similar profile trends to the m/z 
1272 spectra and the variation of fucosylation continues between strains. This 
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ion has one additional hexose residue compared to m/z 1272. The location of 
this hexose is on the outer arm of the branched m/z 667 structure in the NF299 
strain and is found as an internal residue in the N2 strain (Figure 41). The 
NF299 strain preserves the Gal-Fuc-GlcNAc ion peak (m/z646) that is mostly 
absent in N2. Additionally, the peak that correlates to a neutral loss of a terminal 
fucose (m/z 1288) is scarcely detectable in the NF299 spectrum. The majority of 
peak ions in the NF299 profile strongly point to the expression of the core 
modified structure over the bi-antennary and bisecting core structures found in 
N2. 
Consistently the NF299 strain illustrates a reduction of terminal 
fucosylation of A/-glycans. Similar to the analysis in the previous 
GlcNAc2Man5Fuc chapter, the extent of fucosylation was quantified by observing 
the abundance of fucosylated B-ions in the MS/MS spectra. This analysis 
demonstrates the decrease of terminal fucose in NF299. The most abundant B-
ion peak in the wild-type N2 was m/z 1272 (GlcNAcMan4Fuc) and encompasses 
32.7% of GlcNAc2Man5Fuc2 structures. Conversely the abundance of this ion in 
the NF299 strain is 9.1%. Fucose residues in NF299 are found primarily on the 
core GlcNac residues. This conclusion is drawn from two observations: 1) the B-
ion quantification in Table 10 shows that the sum of B-ions in only 12.8% for 
NF299 compared to 41.1 % in N2. As a result the location of fucose must be 
found on the reducing end GlcNAc in the corresponding Y-ion. 2) In B-ions from 
NF299 that do have fucose, the ions generated in the MS3 spectra indicate the 
fucose is linked to the penultimate GlcNAc with an additional hexose residue and 
less likely on terminal residues common in N2. 
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Figure 41. MS3 of m/z 1476 from GlcNAc2Man5Fuc2. The spectra of N2 and 
NF299 strains differ notably. The NF299 strain generates a greater amount of 
the structures shown at the top right, whereas N2 predominatly expresses the 
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6.9 ± 2.0% 
7.3 ± 3.0% 
1.1 ±0.5% 
NF299 (k179) 
27.2 ± 1.6% 
51.8 ± 2.2% 
9.1 ±2 .1% 
8.2 ± 2.0% 
3.4 ± 0.4% 
0.3 ±0 .1% 
Table 10. Relative intensity of MS/MS B-fragments from GlcNAc2Man5Fuc2. This 
table shows the deviation of outer-arm fucosylation the NF299 strain compared to the 
wild-type N2 strain. The percent relative intensity each composition was calculated 
based on the measured intensity of both fucosylated and non-fucosylated outer arm B-
ions from three individual experiments. 
129 
6.2.8 Structural Characterization of GlcNAcpMansFucg 
The most noticable observation of tri-fucosylated compositions in the 
NF299 strain is the considerable decreased abundance compared to N2. The N-
glycome of the N2 strain boasts 19% tri-fucosylated compositions whereas 
NF299 only contains 12%. Of all the tri-fucosylated structures in the N2 
glycome, GlcNAc2Man5FuC3 is the most abundant. The MS/MS profile of this 
composition has four B/Y ion compositions (m/z490/1651, m/z 664/1476, m/z 
694/1446 and m/z 868/1272). The m/z 1651 B-ion peak is absent in NF299 and 
the m/z 1446 B-ion peak is notably reduced, both of which contain two fucose 
residues (Figure 42). Similar to the analysis of B-ion compositions with two 
fucose residues in the GlcNAc2Man5Fuc2, the GlcNAc2Man5Fuc3 analysis in 
NF299 is also limited due to the small abundance of these structures. 
Additonally, the tri-fucosylated structures are overall less abundant in the N-
glycome than di-fucosylated compositions. As a result the structural mining is 
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Figure 42. MS2 of GlcNAc2Hex5Fuc3 (m/z 10702+). B/Y ion complementation 
from MS/MS profiles of m/z 10702+ from the two strains reveals the decrease of 
outer arm fucosylation in NF299 compared to N2. This is evident from the 
decrease of m/z 1651 and m/z 1446. Open circle, glactose; filled circle, mannose; 
filled triangle, fucose; filled square, A/-acetylglucosamine. 
The MS3 spectra of the m/z 1272 B-ion peaks (GlcNAcMan4Fuc) have 
noticable differences between strains (Figure 43). The MS3 spectra of the m/z Y-
ion peaks are similar between strains (Figure D9). The trend of the NF299 to 
either lack or have decreased terminal fucose continues and is evident from the 
m/z 723, m/z 1027, m/z 1045, m/z 1084 and m/z 1115 peaks. Also, the 
presence of other peaks (m/z 646, m/z737, m/z 649 and m/z 667), which are 
largley absent in N2, point to an increase in penultimate GlcNAc modifications. 
Interestingly, is the presence of the m/z 667 peak that in previous compositions 
was established as a linear and branched tri-mannosyl structure. 
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Figure 43. MS3 of m/z 1272 from GlcNAc2Man5Fuc2. The spectra of N2 and 
NF299 strains differ notably. The NF299 strain generates a greater amount of 
the structures shown at the top right and bottom, whereas N2 predominatly 
expresses the structure at the top left. 
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In this case, MSn of m/z667 from NF299 shows evidence for both the 
linear and branched structures (Figure 44). The m/z 563 peak can only be 
created from a linear structure. However, the remaining peaks can be generated 
from both structures and this MSn spectrum is not conclusive to rule out any 
isomer. The m/z 399 peak that is unique to the branched structure is not 
detected. Likewise, the m/z227 peak that is unique to the linear structure and is 
present in previous m/z 667 peak fragment profiles, is not represented in this 
spectrum. 
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Figure 44. MS4 spectra and fragmentation assignments of m/z 667 
from GlcNAc2Man5Fuc3. Isolation and fragmentation of the m/z 667 C-
type ion (three terminal mannose residues) reveals the presence of three 
isomers based on the presence of the m/z 563 peak that can only be 
created from a linear structure. 
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Further fragmentation of the the m/z 1272 B-ion (10702+^1272-+1054), 
illustrates the significant difference between strains (Figure 45). The loss of a 
terminal hexose from m/z 1272 in N2 results primarily in a m/z 809 peak, which 
is not observed in NF299. This peak is the neutral loss of a non-modified 
GlcNAc residue. The structure of the NF299 m/z 1272 B-ion is primarily the hex-
fuc modified GlcNAc, evident from peaks m/z 433, m/z 646 and m/z 667. The 
m/z 880 peak results from the neautral loss of the hex-fuc disaccharide, which is 
not illustrated in Figure 45. 
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Figure 45. MS4 of m/z 1054 from GlcNAc2Man5Fuc2(10702+->1272^1054). 
The NF299 strain generates a greater amount of the structures shown at the 
top right, whereas N2 predominantly expresses the structure at the top left and 
bottom. 
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Isolation and fragmentation of the m/z 1476 B-ion peak (GlcNAcMan5Fuc) 
shows similarity to the other mono-fucosylated B-ion analyzed above (m/z 1272) 
(Figure 46). That is terminal fucosylation in the NF299 strain is not equivalent to 
the N2 strain. Similar peaks are present in NF299 that are not in N2 (m/z646 
and m/z 911). The NF299 strain lacks higher m/z peaks that correspond to the 
neutral loss of an internal GlcNAc (-245). Particularly observed from the m/z 
1231 and m/z 1319 ions. Also, the MS3 spectra of the m/z Y-ion peaks are 
similar between strains (Figure D9). 
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Figure 46. MS3 of m/z 1476 from GlcNAc2Man5Fuc3. NF299 generates a 
greater amount of the structures shown at the top right, whereas N2 
predominatly expresses the structure at the top left and bottom. 
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The m/z 1446 and m/z 1650 peaks, which are mostly absent in the NF299 
strain, have fucose residues linked to the penultimate GlcNAc residue or at the 
terminus of the structure in the N2 strain (Figures 47 and 48). The MS3 spectra 
from NF299 are too poor to make any accurate conclusions and therefore it can 
be concluded that these structures are generated in insignificant quantities. The 
MS3 spectra of the m/z Y-ion peaks are similar between strains, but the weak 
signal of NF299 is evident in these profiles (Figure D11 and D12). It also 
appears in N2 that the penultimate GlcNAc is always modified with a hex-fuc 
disaccharide (m/z 646) from the absence of a m/z 1201 and m/z 1405 (245 
neutral loss of an internal GlcNAc) in the m/z 1446 and m/z 1650 profiles 
respectfully. That is to say that the structures in N2 do not have two terminal 
fucose residues. One fucose is attached to the GlcNAc and the second is on the 
terminus of one antenna. The NF299 strain does not add fucose to the terminus 
of /V-glycans (Table 11). Specifically, NF299 does not readily generate /V-glycans 
with two fucose residues distal from the reducing end GlcNAc. 
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Figure 47. MS3 of m/z 1446 from GlcNAc2Man5Fuc3(10702+-*1446) in N2. 
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Figure 48. MS3 of m/z 1650 from GlcNAc2Man5Fuc3(10702+^1650) in N2. 
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Relative Intensity 
N2 (Bristol) 
79.4 ± 4.4% 
14.1 ±2.5% 
4.6 ± 1.5% 
1.9 ±1.2% 
NF299 (k179) 
80.4 ± 1.0% 
3.1 ±0.5% 
15.6 ±1.5% 
0.9 ± 0.3% 
Table 11. Relative intensity of MS/MS B-fragments from GlcNAc2Man5Fuc3. This 
table shows the increased decrease of outer-arm fucosylation the NF299 strian 
compared to the wild-type N2 strain. The percent relative intensity each composition 
was calculated based on the measured intensity of both fucosylated and non-
fucosylated outer arm B-ions from three individual experiments. 
138 
6.2.9 Structural Characterization of GlcNAcpMan^Fuc^ 
The final composition to be analyzed is GlcNAc2Man5Fuc4. From the 
complete A/-glycome analysis obtained from the MALDI-TOF profiles, the 
existence of tetra-fucosylated compositions in NF299 cogc-1(k179) is roughly 
1%. It is important to note that baseline peaks inherent in the spectrum may 
account for this percentage and not necessarily a true glycan. MS/MS of any 
peak confirms the presence of carbohydrates based on the peak generated. 
Comparatively tetra-fucosylated structures comprise 9% in N2 strains. MS" of 
GlcNAc2Man5Fuc4 in the N2 strain confirms the presence of one B/Y ion 
complement (m/z 1446 and 868). However, the MS/MS profile of NF299 does 
not contain these peaks or any other ions B/Y ions that could be generated from 
GlcNAc2Man5Fuc4 (m/z 11572+or 2291) (Figure 49). There are three peaks in 
both spectra that correspond to carbohydrate compositions {m/z 490, m/z 690 
and m/z 894). MSn of the m/z 1446 B-ion and m/z 868 Y-ion confirms the 
structure and its likeness to m/z 1446 from the GlcNAc2Man5Fuc3 composition in 
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Figure 49. MS2 of GlcNAc2Man5Fuc4 {m/z 11572+). B/Y ion 
complementation from MS/MS profiles of m/z 11572+ shows only one N-
glycan composition in N2. The NF299 does not contain any obvious 
GlcNAc2Man5Fuc4 structure. Open circle, galactose; filled circle, mannose; 
filled triangle, fucose; filled square, A/-acetylglucosamine. 
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Figure 50. MS" of m/z 1446 from GlcNAc2Man5Fuc4. Fragmentation of the 
m/z 841 peak from m/z 1446 B-ion illustrates the presence of a branched 
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Figure 51. MS3 of m/z 868 from GlcNAc2Man5Fuc4. Fragmentation of the 
m/z 868 peak confirms the structure of the reducing end Y-ion (complement 
of the m/z 1446 B-ion). 
The three peaks that correspond to a carbohydrates m/z composition in 
the NF299 spectrum are m/z 490, m/z 690 and m/z 894. The MS3 spectra 
demonstrate that the fragments of m/z 490 and m/z 690 can be assigned to 
carbohydrates. The m/z 490 ion corresponds to a fucosylated reducing end 
GlcNAc and the m/z 690 is a Man2GlcNAc composition. Interestingly, the sum of 
the m/z 490 and m/z 690 peaks is 1157. It is likely that these two ions are B/Y 
complements of the singly charged m/z 1157 GlcNAc2Man2Fuc composition that 
is inherently included from the isolation of the doubly charged (11572 
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Figure 52. MSJof m/z 490 and m/z 690 from 1157 . 
The presence of the m/z 894 peak in both sample spectra is also a 
product of a low molecular weight glycan carried over during the isolation of the 
doubly charged GlcNAc2Man5Fuc4 composition (11572+). The m/z 894 peak with 
the addition of a reducing end GlcNAc residue, has a sodiated m/z value of 
1187. This ion would not be selected from the m/z 1157 isolation window 
speculated on the ion trap. However if this composition (GlcNAc2Man3), which is 
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a documented A/-glycan in C. elegans (Cipollo, Costello et al. 2002), is under-
permethylated then its mass would be 1157. In any case, the NF299 strain and 
N2 strain differ considerably with NF299 lacking any GlcNAc2Man5Fuc4 
composition in its glycome. The absence of this structure in NF299 further 
supports the role of the conserved oligomeric Golgi complex in terminal 
fucosylation in C. elegans. 
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Glycosylation is a complex process that involves a substantial fraction of 
cellular components. The correlation between glycan related gene transcription, 
biosynthesis and glycan structure is one aspect of glycobiology that remains 
poorly understood. Even more confounding is the connection between a 
particular glycan structure and its biological function. It is known that defects in 
the glycosylation pathway are severely life threatening and the occurrence of 
these diseases is exponential. Recent developments have enabled more robust 
and accurate screening and diagnoses, but treatment and cure are wanting. 
There is urgent need for new strategies to address the treatment of CDG and 
understand the pathology and inheritance, both of which are virtually unknown. 
One goal of the CDG Family Network is to look for means of improving the 
symptoms of CDG illness. The most puzzling feature of CDG diseases is the 
range of symptoms and severity of disease. This holds true between individuals 
who share identical gene defects. Not considering possible environmental 
aspects that may influence the spectrum of clinical phenotypes, the severity of 
CDG is a product of partial defects in two or more genes in the same pathway. 
This phenomenon, also known as synergistic heterozygosity, is rarely considered 
among CDG patients. Although no cure is available, a list of potential genes to 
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screen and treat could reduce the severity of the disease to a state where 
supportive therapy would increase the quality of life. The list of 512 tunicamycin 
hypersensitive genes represents only one half of the C. elegans genome. Future 
work would include a second screen of previously untested genes not 
represented in the version 1.1 ORFeome RNAi library. Optimistically, this list of. 
tunicamycin-hypersensitive genes could be used as a routine screen to 
categorized additional disorders and reduce the clinical severity of CDG 
diseases. 
A second goal of the CDG Family Network is to identify further types of 
CDG and determine their symptoms and outcomes. CDG awareness is rapidly 
expanding and the possibility of subtypes is only limited by the number of genes 
involved in the biosynthesis of glycans. Currently this number is roughly 200, but 
the number of known CDGs is 18. The identification of subtypes is difficult, but 
relating the biological consequence to its gene defect is considerably 
complicated. Most recently, there has been a rapidly expanding group of 
patients with novel CDG type II defects involving subunits of the conserved 
oligomeric Golgi (COG) complex (CDG-ll/COG-1, CDG-lle and CDG-llh). Little 
is known about the role of the COG complex and its implication in N- and O-
glycan synthesis. Hence, understanding the role of the COG complex in 
glycosylation is the first step in determining an acceptable clinical treatment or 
course of action. Unfortunately only two viable forms of COG deficient CDG 
models exist. Both are single gene knockouts in C. elegans and Chinese 
145 
hamster ovary cells resulting in CDG-ll/COG-1 like illness. Although there are 
CDG diseases of subunits 7 and 8, no animal models exist. 
The comparative analysis of N2 (Bristol) and NF299(/cf 73) has led to the 
identification of defects of terminal fucosylation of A/-linked glycans on all 
glycoproteins in CDG-ll/COG-1 conditions. The biological significance of 
fucosylation is fairly understood and ranges from tissue development, 
angiogenesis, fertilization, cell adhesion inflammation, cancer metastasis to 
invasion of bacteria, parasites and viruses (Listinsky, Siegal et al. 1998; Ma, 
Simala-Grant et al. 2006). An increase in fucosylation is implicated in 
inflammation and cancer (Miyoshi, Moriwaki et al. 2008). Additional studies 
found that outer arm fucosylation (attached to GlcNAc via an alpha 1-3/4 linkage) 
is significantly increased in the serum of hepatocellular carcinoma patients 
(Tanabe, Deguchi et al. 2008). Notch signaling relies heavily on Ofucosylation. 
Defects of Ofucosylation of Notch is embryonic lethal in mice (Chen, Lu et al. 
2006). 
Moreover, defects of the GDP-fucose transporter on the Golgi cause 
Leukocyte Adhesion Defficiency (LAD)/CDG-llc (Sturla, Rampal et al. 2003). 
LAD/CDG-llc is characterized by reduced expression of fucosylated 
glycoconjugates, specifically blood group H and Lewis antigens (Etzioni, 
Frydman et al. 1992). Hypofucosylated structures include ligands (leukocytes) 
for the selectin family of adhesion molecules. The result caused a reduction of 
leukocyte rolling on endothelial cells which is mediated by selectins. This 
inability of selectins to identify their glycan ligands impairs the recruitment of 
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leukocytes into inflamed tissues. Data supports the concept that A/-glycans are 
primarily affected in LAD/CDG-llc patients, where fucose additions are found on 
the reducing end GlcNAc or as terminal modifications. 
Traditionally the regulation of fucosylation depends on 
fucosyltransferases, GDP-fucose synthetic enzymes, GDP-fucose transporters 
and lysosomal fucosidases. In addition to these components, this study showed 
that the COG complex acts as non-direct factor of fucosylation in C. elegans. 
Consequently the COG complex is required for proper function of the 
glycosylation machinery via intracellular trafficking. The lack of fucosylation in C. 
elegans has an effect on its development and brood size, but interestingly the 
strain NF299 cogc-1(k179) remains viable. 
As the discovery of glycan structural variations increases and the number 
of enzymes enlisted to create these structures remains the same, it is crucial to 
consider other molecular mechanisms by which the Golgi functions that gives 
rise to glycan diversity. Furthermore, the pathogenic mechanisms linking 
glycosylation defects to clinical presentations in CDG cases remains to be 
elucidated. The key to understanding the systems that underlie and control 
glycosylation lies in animal models of CDG genetic defects. This approach not 
only found trends of fucosylation in CDG-ll/COG-1, but also provides a target for 
pharmacological intervention where a disruption in outer arm fucosylation is 
warranted, such as tumor metastasis, inflation or graft rejection. 
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TUNICAMYCIN HYPERSENSITIVE LOCI 
The genome-wide RNAi screen resulted in 512 genes that are 
hypersensitive to tunicamycin (Table A1). The C. elegans gene sequence name 
and gene name are given. As stated in Chapter 5.1, the effects of RNAi 
penetrance and expressivity were measured. The values below (Exp and Pen) 
are the difference between drug treated scores from non-drug treated scores. 
Additionally, the presence of A/-glycosylation sites and cellular location were 
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APPENDIX B 
NATIVE AND PERMETHYLATED MALDI-TOF SPECTRA 
The spectra in this section represent MALDI-TOF profiles of both native 
and permethylated A/-linked glycans from N2 Bristol (wild-type) and NF299 (cogc-
1)k179 C. elegans strains. All glycans were released with hydrazine. The 
comparative analysis consisted of three individual trials from synchronized L1 
larvae from each strain to the final permethylation step of reduced 
oligosaccharides. The native profiles show the presence of endogenous O-
methylated A/-glycans that are not detectable after the permethylation step. 
All figures show the N2 strain profiles above the NF299 samples. The 


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































RELATIVE ABUNDANCE OF NATIVE A/-GLYCANS 
Comparative analysis of native A/-glycans form N2 and NF299. The 
analysis is based on the population mean of three individual samples for each 
strain run simultaneously. Compositions present Table C1 include pauci-40 
nnose, high-mannose, fucose rich, truncated complex and endogenous O-
methylated /V-glycans. N=HexNAc (e.g. N-acetylglucosamine, N-
acetylgalactosamine), H=Hexose (e.g. galactose, mannose, glucose), 
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ADDITIONAL MSn SPECTRA 
MSn profiles from Man5Fi-4. The majority of spectra are the MS3 of Y-ion 
complements not included in Chapter 6. These ions are reducing end GlcNAc 
residues with fucose and hexose (galactose) additions. 
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